ndd_id	patient_id	tumor_tissue	tumor_type_detail	gene	mutation_type	mutation	position	mt_peptide	wt_peptide	length	chromosome	genomic_coord	ref	alt	HLA	response_type	assay_type	effector_origin	stimulation_target	presentation_method	netmhcpan_rank	netmhcstabpan_stability	prime_rank	bigmhc_im_score	tap_score	netchop_score	dai_netmhcpan	anchor_mutation	eluted_ligand_match	tcga_cancer_expression_tpm_median	driver_status	pubmed_id	reference_name
NDDR-8Y7QQTRFWC-U	GEXOATK7	Skin	Skin Cutaneous Melanoma	WDR46	SNV	p.T227I	3	FLIYLDVSV	FLTYLDVSV	9	6	33287207	G	A	HLA-A02:01	CD8	"ELISPOT, ICS"	patient_TIL	"peptide_pulsed_APC, tumor_cells"	none	0.123	0.17	0.124	0.5000206	0.2	0.152263	-0.198450939	no	1	5.306262756328292		PMID:33303615	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
NDDR-2HJHFX0EFJ-0	GEXOATK7	Skin	Skin Cutaneous Melanoma	AHNAK	SNV	p.S4460F	1	FMPDFDLHL	SMPDFDLHL	9	11	62526678	G	A	HLA-A02:01	CD8	"ELISPOT, ICS, multimer"	patient_TIL	peptide_pulsed_APC	none	0.057	0.3	0.053	0.58284676	0.782	0.978539	-0.816761137	no	1	4.897806285758671	Other Tumor Driver	PMID:33303615	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
NDDR-M2GXDWKP1W-D	ZWHDI5GT	Skin	Skin Cutaneous Melanoma	GNB5	SNV	p.P377L	9	RVSTLRVSL	RVSTLRVSP	9	15	52124519	G	A	HLA-B07:02	CD8	"ELISPOT, ICS"	patient_TIL	peptide_pulsed_APC	none	0.139	0.8	0.088	0.47644085	1.286	0.034531	-3.43537867	no	0	0.3897319869389105		PMID:33303615	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer
NDDR-JRGCAYDCQA-S	6FHDB5EK	Skin	Skin Cutaneous Melanoma	TRAPPC1	SNV	p.R129G	4	FRSGLDSYV	FRSRLDSYV	9	17	7930659	G	C	HLA-C06:02	CD8	"51Cr, HLA-block"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.1	29	0.018	0.38020083	0.366	0.73499	-0.418710335	no	1	5.942411031709106		PMID:10582700	Two antigens recognized by autologous cytolytic T lymphocytes on a Melanoma result from a single point mutation
NDDR-VXMQ2DHCNY-F	DAXCBTFA	Skin	Skin Cutaneous Melanoma	TRAPPC1	SNV	p.R129G	7	SELFRSGLDSY	SELFRSRLDSY	11	17	7930659	G	C	HLA-B44:02	CD8	"51Cr, HLA-block"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.266	0.4	0.581	0.052168835	3.04	0.763436	0.158546291	no	1	5.942411031709106		PMID:10582700	Two antigens recognized by autologous cytolytic T lymphocytes on a Melanoma result from a single point mutation
NDDR-AHCH9CD88T-A	M4HZA63S	Skin	Skin Cutaneous Melanoma	HERV-K-MEL	SNV	p.V102I	5	MLAVISCAV	MLAVVSCAV	9					HLA-A02:01	CD8	"51Cr, HLA-block"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	1.022	0.3	0.553	0.41658655	0.378		-0.068992871	no	0			PMID:12359761	A human endogenous retroviral sequence encoding an antigen recognized on Melanoma by cytolytic T lymphocytes
NDDR-MG2GYB7FKK-1	LFXUCEDT	Skin	Skin Cutaneous Melanoma	PRDX5	SNV	p.S79L	6	LLLDDLLVSI	LLLDDSLVSI	10	11	64321032	C	T	HLA-A02:01	CD8	"51Cr, HLA-block, multimer"	"patient_Tc_line, patient_TIL"	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.171	0.4	0.046	0.5359305	0.624	0.954141	0.047913356	no	1	7.683650482276308		PMID:15695408	Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic Melanoma and targeted by CD8(+) T cells with a memory phenotype
NDDR-3Q45K91QR4-F	D35NTCNS	Skin	Skin Cutaneous Melanoma	MYO1B	SNV	p.E911K	1	KINKNPKYK	EINKNPKYK	9	2	191414079	G	A	HLA-A03:01	CD8	"51Cr, HLA-block, multimer"	"patient_Tc_line, patient_TIL"	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.024	0.2	0.013	0.44635656	0.552	0.634706	-4.044512188	no	1	3.642421814668846		PMID:10064075	A natural cytotoxic T cell response in a spontaneously regressing human Melanoma targets a neoantigen resulting from a somatic point mutation
NDDR-4HG2AETK8S-9	V4WFIEVK	Lung	Non-Small Cell Lung Cancer (NSCLC)	NFYC	SNV	p.Q241K	6	AQQITKTEV	AQQITQTEV	9					HLA-B52:01	CD8	"51Cr, HLA-block"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.454	7	0.023	0.16051857	0.728		0.260164044	no	0	3.0712220719161376		PMID:16287085	A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma
NDDR-BD6M2KY4NN-4	V4WFIEVK	Lung	Non-Small Cell Lung Cancer (NSCLC)	NFYC	SNV	p.Q241K	5	QQITKTEV	QQITQTEV	8	1	40769362	C	A	HLA-B52:01	CD8	"51Cr, HLA-block"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.885	3	0.473	0.6644128	0.524		0.162851321	no	0	3.0712220719161376		PMID:16287085	A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma
NDDR-7SABVDNYFG-Y	TSXDFNM6	Head & Neck	Head and Neck Squamous Cell Carcinoma	TP53	SNV	p.Y220C	4	VVPCEPPEV	VVPYEPPEV	9					HLA-A02:01	CD8	"51Cr, HLA-block"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.751	9	1.073	0.3173151	0.454	0.687508	0.629941105	no	1	3.293914439591016	Tumor Driver	PMID:17294448	Immunological characterization of missense mutations occurring within cytotoxic T cell defined p53 epitopes in HLA A0201 squamous cell carcinomas of the head and neck
NDDR-GSSA542C57-I	7LJZLSYK	Skin	Skin Cutaneous Melanoma	ENTPD4	SNV	p.P85L	7	ATDTNNLNVNY	ATDTNNPNVNY	11	8	23447838	G	A	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	none	2.391	4.5	1.282	0.36449605	2.864	0.96242	0.671222828	no	0	3.1196292036020346		PMID:33038342	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
NDDR-SGEY1B756Q-7	7LJZLSYK	Skin	Skin Cutaneous Melanoma	TTC37	SNV	p.A692V	6	YLDGKVVDY	YLDGKAVDY	9	5	95520755	G	A	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	none	3.937	35	11.33	0.3075591	2.426		-0.116625252	no	0	3.00543587954074		PMID:33038342	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
NDDR-WSV1MDSJB6-H	TFT6DO6A	Skin	Skin Cutaneous Melanoma	ARMT1	SNV	p.P286L	2	FYGKTILWF	FPGKTILWF	9	6	151468641	C	T	HLA-A24:02	CD8	"ELISPOT, ICS, multimer"	PBMC_postVax	peptide_pulsed_APC	none	0.052	0.25	0.02	0.35181832	2.108		-4.193145147	no	0	2.896756166453227		PMID:30880120	Identification of a neoantigen epitope in a Melanoma patient with good response to anti-PD-1 antibody therapy
NDDR-XMMWH86R9X-E	FNWFEVPE	Cerebellum/Posterior fossa	Medulloblastoma (pediatric)	PDCD10	SNV	p.A74P	4	IASPIKEL	IASAIKEL	8	3	167687680	C	G	HLA-C12:02	CD8	"ELISPOT, ICS, multimer"	"patient_Tc_line, PBMC_pre"	peptide_pulsed_APC	none	0.234	2.5	3.957	0.14958204	0.99	0.48951	-1.082818708	no	0			PMID:31351799	Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
NDDR-BBEYF3X3HN-4	FNWFEVPE	Cerebellum/Posterior fossa	Medulloblastoma (pediatric)	PDCD10	SNV	p.A74P	10	LQTIKDIASPI	LQTIKDIASAI	11	3	167687680	C	G	HLA-B52:01	CD8	"ELISPOT, ICS, multimer"	"patient_Tc_line, PBMC_pre"	peptide_pulsed_APC	none	7.046	0.4	10.695	0.000386612	0.728	0.897295	0.649003997	no	0			PMID:31351799	Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
NDDR-8FNTWKZDFG-Y	FU5SPZUA	Cerebellum/Posterior fossa	Medulloblastoma (pediatric)	TSEN54	SNV	p.R472Q	2	AQMCISGF	ARMCISGF	8	17	75523764	G	A	HLA-C12:03	CD8	"ELISPOT, ICS, multimer"	"patient_Tc_line, PBMC_pre"	peptide_pulsed_APC	none	22.864	1.2	33.066	0.003008314	3.142	0.307014	-0.193672219	yes	0			PMID:31351799	Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
NDDR-JDQYDNJXFT-A	FU5SPZUA	Cerebellum/Posterior fossa	Medulloblastoma (pediatric)	PCSK9	SNV	p.V202F	11	DHREIEGRVMF	DHREIEGRVMV	11	1	55052358	G	T	HLA-B18:01	CD8	"ELISPOT, ICS, multimer"	"patient_Tc_line, PBMC_pre"	peptide_pulsed_APC	none	0.158	12	1.548	0.14563482	2.264	0.536006	-2.522178045	no	0			PMID:31351799	Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
NDDR-0J9XF0AJTT-A	FU5SPZUA	Cerebellum/Posterior fossa	Medulloblastoma (pediatric)	PCSK9	SNV	p.V202F	1	FTDFENVP	VTDFENVP	8	1	55052358	G	T	HLA-C05:01	CD8	"ELISPOT, ICS, multimer"	"patient_Tc_line, PBMC_pre"	peptide_pulsed_APC	none	9.493	45	8.173	0.14667054	-0.474	0.405231	-0.296778883	no	0			PMID:31351799	Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
NDDR-0V67NT0BT2-D	FU5SPZUA	Cerebellum/Posterior fossa	Medulloblastoma (pediatric)	NEU2	SNV	p.L234T	9	KTGEQRVVTL	KTGEQRVVLL	10	2	233034587	G	A	HLA-C12:03	CD8	"ELISPOT, ICS, multimer"	"patient_Tc_line, PBMC_pre"	peptide_pulsed_APC	none	9.571	5.5	5.727	0.004257361	0.814		-0.381033667	yes	0			PMID:31351799	Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
NDDR-9A9KVDPVGD-V	FU5SPZUA	Cerebellum/Posterior fossa	Medulloblastoma (pediatric)	SVIL	SNV	p.D1285N	8	RTDVKAYNVT	RTDVKAYDVT	10					HLA-C05:01	CD8	"ELISPOT, ICS, multimer"	"patient_Tc_line, PBMC_pre"	peptide_pulsed_APC	none	12.052	31	3.575	0.17577124	-0.81	0.027018	-0.395570092	no	0			PMID:31351799	Low mutational load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell immunotherapy
NDDR-NB93YAHBJ0-B	4V2JUJEQ	Liver	Hepatocellular Carcinoma	C5orf42	SNV	p.I1134K	13	DADILSETFQLLK	DADILSETFQLLI	13	5	37201697	A	T	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, patient_Tc_line"	peptide_pulsed_APC	none	12.983	5.5	2.664	0.15842223			-1.879010447	no	0			PMID:31887370	Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
NDDR-1YAP0FVN2C-U	4V2JUJEQ	Liver	Hepatocellular Carcinoma	C5orf42	SNV	p.I1134K	11	DILSETFQLLK	DILSETFQLLI	11	5	37201697	A	T	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, patient_Tc_line"	peptide_pulsed_APC	none	3.101	1.8	0.978	0.09473962	0.296		-2.962619922	no	0			PMID:31887370	Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
NDDR-0T85G4PK4N-4	4V2JUJEQ	Liver	Hepatocellular Carcinoma	C5orf42	SNV	p.I1134K	10	ILSETFQLLK	ILSETFQLLI	10	5	37201697	A	T	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, patient_Tc_line"	peptide_pulsed_APC	none	0.675	0.5	0.762	0.07246435	0.432		-3.858778491	no	0			PMID:31887370	Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
NDDR-JPW6QH0ZNW-D	4V2JUJEQ	Liver	Hepatocellular Carcinoma	C5orf42	SNV	p.I1134K	9	LSETFQLLK	LSETFQLLI	9	5	37201697	A	T	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, patient_Tc_line"	peptide_pulsed_APC	none	0.544	1.2	0.28	0.12192804	0.316		-3.752958311	no	0			PMID:31887370	Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma
NDDR-AREYVJW6QB-T	3RRUMLDF	Skin	Skin Cutaneous Melanoma	DCAKD	SNV	p.S199F	2	RFLEYLPLRF	RSLEYLPLRF	10	17	45024533	G	A	HLA-A24:02	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	0.104	0.12	0.187	0.36792213	2.9	0.55062	-2.739598559	no	1	3.732597332974641		PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-NPWGNEDF13-E	G4ZPYEDM	Skin	Skin Cutaneous Melanoma	DDX3X	SNV	p.E388K	4	FPKKIQMLA	FPKEIQMLA	9	X	41345316	G	A	HLA-B56:01	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	0.006	0.07	0.347	0.83115304	-1.374	0.920179	0.405465108	no	0	4.161427619593944	Tumor Driver	PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-1RZ65VX580-B	G4ZPYEDM	Skin	Skin Cutaneous Melanoma	ITGA9	SNV	p.L548P	7	VTEKLQPTY	VTEKLQLTY	9	3	37542539	T	C	HLA-A01:01	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	0.02	0.12	0.02	0.28144857	2.714	0.946856	1.609437912	no	0	1.3090999275179485		PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-5NDTKW9WVC-U	G6DBM54G	Skin	Skin Cutaneous Melanoma	VPS16	SNV	p.S404F	5	LRAAFFGKCF	LRAASFGKCF	10	20	2862814	C	T	HLA-B27:05	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	2.327	0.8	0.612	0.41129395	2.934	0.412664	-0.018731923	no	0	3.7031671368041055		PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-MHSQEBMGSW-D	G6DBM54G	Skin	Skin Cutaneous Melanoma	CIT	SNV	p.P2056L	4	VRTLLSQVNK	VRTPLSQVNK	10	12	119690296	G	A	HLA-B27:05	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	0.829	0.4	1.059	0.6598468	0.756	0.817271	0.57818275	no	0	0.6508097074039529		PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-M431P5K4KM-3	G6DBM54G	Skin	Skin Cutaneous Melanoma	CASP1	SNV	p.P172S	8	WRNILLLSLH	WRNILLLPLH	10	11	105041480	G	A	HLA-B27:05	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	2.113	1.2	0.462	0.7958803	-0.566		-0.025234984	no	0	2.918489810532816		PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-YZD3GSV3PV-C	F3XRZQLP	Skin	Skin Cutaneous Melanoma	FAM200A	SNV	p.S116F	9	IPLSDNTIF	IPLSDNTIS	9	7	99548061	G	A	HLA-B35:01	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	0.049	0.12	0.039	0.5422627	1.964	0.042772	-4.541121341	yes	0	1.9769849273236493		PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-QFKBAJAWPA-S	F3XRZQLP	Skin	Skin Cutaneous Melanoma	GRIN2B	SNV	p.E1104K	5	REFDKIELAY	REFDEIELAY	10	12	13563928	C	T	HLA-B41:02	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	0.527	2.5	0.137	0.47341612	3.384	0.977014	-0.564753017	no	0	-7.861447624847352		PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-3FYD6RDVNQ-7	F3XRZQLP	Skin	Skin Cutaneous Melanoma	TBX4	SNV	p.S271F	5	YPVIFKSIM	YPVISKSIM	9	17	61480110	C	T	HLA-B35:01	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	0.083	0.08	0.076	0.8534652	-0.268	0.949069	0.170345366	yes	0	-5.357023508242532		PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-J3PXJHBAC2-D	URSBQAUG	Skin	Skin Cutaneous Melanoma	FAM50B	SNV	p.E78K	7	DMKARQKALV	DMKARQEALV	10	6	3850043	G	A	HLA-B08:01	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	0.843	3	3.24	0.6509104	0.1	0.521495	0.064934013	yes	0	2.637760851362445		PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-5G69MS9MJJ-0	3RRUMLDF	Skin	Skin Cutaneous Melanoma	ACPP	SNV	p.E34K	1	KLKFVTLVF	ELKFVTLVF	9	3	132317556	G	A	HLA-A24:02	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	0.978	1.7	0.106	0.2514855	2.69		-0.884713534	no	0			PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-6KW890FEY0-B	3RRUMLDF	Skin	Skin Cutaneous Melanoma	ACPP	SNV	p.E34K	1	KLKFVTLVF	ELKFVTLVF	9	3	132317556	G	A	HLA-B15:01	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	0.049	0.2	0.002	0.3059785	2.69		-2.043073898	no	0			PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-BGT2WPZEN8-J	F3XRZQLP	Skin	Skin Cutaneous Melanoma	COL22A1	SNV	p.D291N	7	FPQGLPNEY	FPQGLPDEY	9	8	138826756	C	T	HLA-B35:01	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	none	0.003	0.09	0.016	0.56636214	2.026	0.818258	0	yes	0	0.9192631801181528		PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-51YCQP8A9M-3	F3XRZQLP	Skin	Skin Cutaneous Melanoma	COL22A1	SNV	p.D291N	3	LPNEYAFVTT	LPDEYAFVTT	10	8	138826756	C	T	HLA-B35:01	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	4.521	1	0.237	0.36414808	-1.422	0.05056	0.028720843	yes	0	0.9192631801181528		PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-B7GMHB69XA-S	F3XRZQLP	Skin	Skin Cutaneous Melanoma	COL22A1	SNV	p.D291N	3	LPNEYAFVT	LPDEYAFVT	9	8	138826756	C	T	HLA-B35:01	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	TMC	0.923	0.5	0.19	0.71816474	-1.422	0.499	-0.327767067	yes	0	0.9192631801181528		PMID:28678778	An immunogenic personal neoantigen vaccine for patients with Melanoma
NDDR-MSZN302K7F-X	DZL67UZM	Skin	Skin Cutaneous Melanoma	CDC37L1	SNV	p.P186L	6	FLSDHLYLV	FLSDHPYLV	9	9	4697144	C	T	HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.002	0.01	0.001	0.73414487	0.054	0.947568	0	no	1	1.3965157022711483		PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-G695BNZBRH-Z	DZL67UZM	Skin	Skin Cutaneous Melanoma	DOPEY2	SNV	p.R365C	4	KPFCVLISL	KPFRVLISL	9	21	36214520	C	T	HLA-B07:02	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.239	0.12	0.015	0.6494463	0.756		1.97995599	no	0			PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-A19KEFTKZ2-D	DZL67UZM	Skin	Skin Cutaneous Melanoma	FLNA	SNV	p.P369L	9	AGQHIAKSLF	AGQHIAKSPF	10	X	154366430	G	A	HLA-B44:02	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	4.19	18	1.837	0.036542095	2.526	0.44498	-0.685119821	no	0	7.162794730001245	Other Tumor Driver	PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-M93AXPJXAK-1	DZL67UZM	Skin	Skin Cutaneous Melanoma	FLNA	SNV	p.P369L	6	HIAKSLFEV	HIAKSPFEV	9	X	154366430	G	A	HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.107	0.4	0.045	0.38504964	0.376	0.884259	-0.655047334	no	1	7.162794730001245	Other Tumor Driver	PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-TSWQ8ED6V6-H	DZL67UZM	Skin	Skin Cutaneous Melanoma	KMT2C	SNV	p.P1984S	3	KPSDTPRPVM	KPPDTPRPVM	10	7	152181961	G	A	HLA-B07:02	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.015	0.1	0.161	0.5348725	-0.126	0.858985	-1.120591195	no	0	1.90735193605836	Tumor Driver	PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-2YDKRK2AD9-K	NGE5BUYC	Skin	Skin Cutaneous Melanoma	TTBK2	SNV	p.S1088L	9	RPHHDQRSL	RPHHDQRSS	9	15	42745988	G	A	HLA-B07:02	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.008	0.05	0.1	0.729896	0.654	0.118015	-4.777020443	no	0	0.1116984543301548		PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-VAPV22ZYG6-H	LC3W5VRX	Skin	Skin Cutaneous Melanoma	KIF26B	SNV	p.N256S	2	SSYTGFANK	SNYTGFANK	9	1	245367135	A	G	HLA-A11:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.007	0.3	0.006	0.3342279	0.99	0.970843	-4.33073334	no	0	1.1247087440778083		PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-KWE7NJQDW7-I	LYXKV47S	Skin	Skin Cutaneous Melanoma	SPOP	SNV	p.N147I	7	FLLDEAIGL	FLLDEANGL	9	17	49619021	T	A	HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.009	0.8	0.042	0.64465654	0.738	0.943178	-0.893817876	no	1	2.900451304280764	Other Tumor Driver	PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-3W2VQMDDEP-6	N6T2LYFN	Skin	Skin Cutaneous Melanoma	RETSAT	SNV	p.P546S	8	HDLGRLHSC	HDLGRLHPC	9	2	85343696	G	A	HLA-B37:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	1.188	13	0.017	0.9232992	-0.304	0.026627	-0.520375835	no	0	4.736423449262938	Other Tumor Driver	PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-GFWC1867QW-D	N6T2LYFN	Skin	Skin Cutaneous Melanoma	RETSAT	SNV	p.P546S	2	HSCVMASLR	HPCVMASLR	9	2	85343696	G	A	HLA-A68:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.84	0.3	0.065	0.37042683	1.5	0.646453	-1.071257405	no	0	4.736423449262938	Other Tumor Driver	PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-KYVW6EZ6RX-E	OKQRI23E	Skin	Skin Cutaneous Melanoma	NARFL	SNV	p.E62K	1	KSQREEVRR	ESQREEVRR	9					HLA-A31:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.411	1.3	0.683	0.025451975	1.666		-2.183066976	no	0			PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-NFN8N8118Y-F	VU5HBL4S	Skin	Skin Cutaneous Melanoma	PPFIA4	SNV	p.S709N	4	MRMNQGVCC	MRMSQGVCC	9	1	203053848	G	A	HLA-B39:06	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.418	0.09	3.039	0.9724981	0.486	0.033837	0.426009637	no	0	-0.786497185381495		PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-73G4NR2F2Q-7	LYXKV47S	Skin	Skin Cutaneous Melanoma	CDK4	SNV	p.R24L	2	ALDPHSGHFV	ARDPHSGHFV	10	12	57751647	C	A	HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.085	1.2	0.065	0.4697877	0.228	0.668099	-4.919637372	no	1	4.89146952891671	Tumor Driver	PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-X3SEE1T450-B	FRMBI3H3	Skin	Skin Cutaneous Melanoma	CLINT1	SNV	p.T472I	4	VSKILPSTW	VSKTLPSTW	9	5	157789479	G	A	HLA-B57:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.006	0.4	0.003	0.8338965	1.018	0.903586	0	no	0	3.647901429523587		PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-19YD017ZK3-E	FRMBI3H3	Skin	Skin Cutaneous Melanoma	COX7A2	SNV	p.A84V	5	GVADVLLYR	GVADALLYR	9	6	75240339	G	A	HLA-A11:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	none	0.021	0.3	0.004	0.74445856	1.534	0.159054	-0.619039208	no	0	5.434168171613791		PMID:28678784	Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
NDDR-B1DKTHN336-H	5DJDBZPW	Skin	Skin Cutaneous Melanoma	SYTL4	SNV	p.S363F	6	GRIAFFLKY	GRIAFSLKY	9	X	100687163	G	A	HLA-B27:05	CD8	"ELISPOT, ICS"	patient_TIL	peptide_pulsed_APC	MS	0.009	0.4	0.001	0.914394	3.272	0.977758	0.117783036	no	1	-2.57304527896216		PMID:27869121	Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry
NDDR-VZ6AX01GXJ-0	5DJDBZPW	Skin	Skin Cutaneous Melanoma	NCAPG2	SNV	p.P333L	2	KLILWRGLK	KPILWRGLK	9	7	158680743	G	A	HLA-A03:01	CD8	ELISPOT	patient_TIL	peptide_pulsed_APC	MS	0.184	0.4	0.122	0.43575552	0.762	0.861472	-3.519785246	no	1	2.653481961494572		PMID:27869121	Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry
NDDR-PBXJS7YJDT-A	5DJDBZPW	Skin	Skin Cutaneous Melanoma	AKAP6	SNV	p.M1482I	6	KLKLPIIMK	KLKLPMIMK	9	14	32822259	G	C	HLA-A03:01	CD8	ELISPOT	patient_TIL	peptide_pulsed_APC	MS	0.006	0.12	0.001	0.46870586	0.62	0.968833	-0.15415068	no	1	-0.3858191584351662		PMID:27869121	Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry
NDDR-WKQY9KFRV9-K	PKPFBJDF	Skin	Skin Cutaneous Melanoma	NOP16	SNV	p.P169L	9	SPGPVKLEL	SPGPVKLEP	9	5	176384171	G	A	HLA-B07:02	CD8	ELISPOT	patient_TIL	peptide_pulsed_APC	MS	0.011	0.7	0.028	0.2350611	0.112		-4.500819262	no	1	2.721894946966146		PMID:27869121	Direct identification of clinically relevant neoepitopes presented on native human Melanoma tissue by mass spectrometry
NDDR-C98AVT8VA9-K	I4HS6WN2	Skin	Skin Cutaneous Melanoma	CSNK1A1	SNV	p.S27L	2	GLFGDIYLA	GSFGDIYLA	9	5	149550885_149550886	TC	CT	HLA-A02:01	CD8	"ELISPOT, ICS"	patient_TIL	peptide_pulsed_APC	none	0.052	1.5	0.046	0.5908489	-0.414	0.312295	-4.006283684	no	1	3.0297071395965185		PMID:23644516	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
NDDR-FF8XNFEPVF-X	74LV6E74	Skin	Skin Cutaneous Melanoma	MATN2	SNV	p.E226K	1	KTLTSVFQK	ETLTSVFQK	9	8	97931486	G	A	HLA-A11:01	CD8	"ELISPOT, ICS"	patient_TIL	peptide_pulsed_APC	none	0.004	0.01	0.001	0.44113854	0.686	0.926989	-3.102342009	no	1	2.15613714562124		PMID:23644516	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
NDDR-894FCPT0FK-1	74LV6E74	Skin	Skin Cutaneous Melanoma	CDK12	SNV	p.E928K	5	CILGKLFTK	CILGELFTK	9	7	40063036	G	A	HLA-A11:01	CD8	"ELISPOT, ICS"	patient_TIL	peptide_pulsed_APC	none	0.279	1.1	0.021	0.14316015	0.56	0.34099	-0.327212911	no	1	2.5695493966620635	Tumor Driver	PMID:23644516	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
NDDR-AYRXPFMZNE-W	74LV6E74	Skin	Skin Cutaneous Melanoma	CDK12	SNV	p.E928K	5	CILGKLFTKK	CILGELFTKK	10	7	40063036	G	A	HLA-A11:01	CD8	"ELISPOT, ICS"	patient_TIL	peptide_pulsed_APC	none	1.908	1.2	0.466	0.20398991	0.56	0.794302	0.048868784	no	0	2.5695493966620635	Tumor Driver	PMID:23644516	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
NDDR-YRY5RYAEAT-A	I4HS6WN2	Skin	Skin Cutaneous Melanoma	CSNK1A1	SNV	p.S27L	2	GLFGDIYLAI	GSFGDIYLAI	10	5	149550885_149550886	TC	CT	HLA-A02:01	CD8	"ELISPOT, ICS"	patient_TIL	peptide_pulsed_APC	none	0.369	0.8	0.185	0.5734593	0.656	0.921601	-3.064454106	no	1	3.0297071395965185		PMID:23644516	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
NDDR-EMJNAQ3KAZ-G	I4HS6WN2	Skin	Skin Cutaneous Melanoma	HAUS3	SNV	p.T160A	7	ILNAMIAKI	ILNAMITKI	9	4	2240469	T	C	HLA-A02:01	CD8	"ELISPOT, ICS"	patient_TIL	peptide_pulsed_APC	none	0.43	0.5	0.15	0.64783394	0.322	0.879551	0.75057923	no	1	0.5219504898143807		PMID:23644516	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
NDDR-BGR5R73328-J	74LV6E74	Skin	Skin Cutaneous Melanoma	MATN2	SNV	p.E226K	1	KTLTSVFQKK	ETLTSVFQKK	10	8	97931486	G	A	HLA-A11:01	CD8	"ELISPOT, ICS"	patient_TIL	peptide_pulsed_APC	none	0.054	0.01	0.069	0.44877782	0.686	0.963817	-2.580497374	no	0	2.15613714562124		PMID:23644516	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
NDDR-545JRB33M5-G	J5PM7M2Y	Skin	Skin Cutaneous Melanoma	PLEKHM2	SNV	p.H1005Y	10	LTDDRLFTCY	LTDDRLFTCH	10	1	15732428	C	T	HLA-A01:01	CD8	"ELISPOT, ICS"	patient_TIL	peptide_pulsed_APC	none	0.009	0.01	0.006	0.6954793	2.652	0.412145	-4.33365305	no	0	5.051104136934164		PMID:23644516	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
NDDR-F477MEXVTB-T	I4HS6WN2	Skin	Skin Cutaneous Melanoma	GAS7	SNV	p.H225Y	9	SLADEAEVYL	SLADEAEVHL	10	17	9934186	G	A	HLA-A02:01	CD8	"ELISPOT, ICS"	patient_TIL	peptide_pulsed_APC	none	0.095	2.5	0.045	0.34322897	1.054	0.969244	-0.408967739	no	1	5.458258899654696		PMID:23644516	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
NDDR-1NGBH26P25-G	J5PM7M2Y	Skin	Skin Cutaneous Melanoma	PPP1R3B	SNV	p.P176H	5	YTDFHCQYV	YTDFPCQYV	9	8	9141125	G	T	HLA-A01:01	CD8	"ELISPOT, ICS"	patient_TIL	peptide_pulsed_APC	none	0.224	1.3	0.005	0.68494403	-0.158	0.901694	-0.117783036	no	1	2.600530749761819		PMID:23644516	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
NDDR-3397S1P89B-T	J5PM7M2Y	Skin	Skin Cutaneous Melanoma	PPP1R3B	SNV	p.P176H	5	YTDFHCQYVK	YTDFPCQYVK	10	8	9141125	G	T	HLA-A01:01	CD8	"ELISPOT, ICS"	patient_TIL	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.841	1.2	0.145	0.48095936	-0.008	0.912707	0.144290612	no	1	2.600530749761819		PMID:23644516	Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
NDDR-4H8V6XSZ4F-X	6K4YGFNF	Skin	Skin Cutaneous Melanoma	KIF16B	SNV	p.L1009P	2	APARLERRHSA	ALARLERRHSA	11	20	16378976	A	G	HLA-B07:02	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.459	0.7	2.211	0.022523178	-0.818	0.78183	-3.67124115	no	0	1.9052529727866243		PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-1C3G4QSC15-G	6K4YGFNF	Skin	Skin Cutaneous Melanoma	FLNA	SNV	p.R2049C	1	CVRVSGQGL	RVRVSGQGL	9	X	154353082	G	A	HLA-B07:02	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	1.384	1.8	0.386	0.06314378	1.114	0.953143	2.305479451	no	0	7.162794730001245	Other Tumor Driver	PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-Y4RAXRTAQJ-0	OGN36M6H	Skin	Skin Cutaneous Melanoma	KIF1BP	SNV	p.P246S	4	AYHSIEWAI	AYHPIEWAI	9					HLA-A24:02	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.206	0.2	0.121	0.15551695	1.012		0.873528873	no	0			PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-1N2HY69Q10-B	OGN36M6H	Skin	Skin Cutaneous Melanoma	KIF1BP	SNV	p.P246S	6	HNAYHSIEWA	HNAYHPIEWA	10					HLA-B38:01	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	33.333	39	3.253	0.028419605	-0.71		0.165808485	no	0			PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-D73BQ8XHHP-6	OGN36M6H	Skin	Skin Cutaneous Melanoma	KIF1BP	SNV	p.P246S	7	EHNAYHSIEWA	EHNAYHPIEWA	11					HLA-B38:01	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	3.934	31	3.421	0.070759766	-1.148		0.122049879	no	0			PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-ZQ6KEKP7NG-Y	OGN36M6H	Skin	Skin Cutaneous Melanoma	KIF1BP	SNV	p.P246S	5	NAYHSIEWAI	NAYHPIEWAI	10					HLA-C12:03	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	7.444	11	3.759	0.021690775	1.216		0.500667825	yes	0			PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-KQX0BHDE2V-C	OGN36M6H	Skin	Skin Cutaneous Melanoma	KIF1BP	SNV	p.P246S	3	YHSIEWAI	YHPIEWAI	8	10	69005862	C	T	HLA-B38:01	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.184	0.5	0.142	0.4799058	0.332		-0.240385358	no	0			PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-WYJW76M06R-8	TOGZJCOT	Skin	Skin Cutaneous Melanoma	PDS5A	SNV	p.Y1000F;H1007Y	"1,8"	FVVPYMIYLL	YVVPYMIHLL	10					HLA-C03:03	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	4.104	4.5	0.127	0.08873232	0.976	0.971609	1.044545067	yes	0	3.1924296896282964		PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-XJ3RMEC41A-S	TOGZJCOT	Skin	Skin Cutaneous Melanoma	MAGEA6	SNV	p.E168K	1	KVDPIGHVY	EVDPIGHVY	9	X	152767149	C	T	HLA-A01:01	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.011	0.02	0.006	0.53820276	2.85	0.975792	0.606135804	no	0	2.919135799116131		PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-BS3218G751-C	TOGZJCOT	Skin	Skin Cutaneous Melanoma	MAGEA6	SNV	p.E168K	1	KVDPIGHVYIF	EVDPIGHVYIF	11					HLA-C05:01	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.207	20	0.147	0.21876486	2.46	0.972332	-1.486205272	no	0	2.919135799116131		PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-YXV2AQ4573-E	TOGZJCOT	Skin	Skin Cutaneous Melanoma	MAGEA6	SNV	p.E168K	3	LMKVDPIGHVY	LMEVDPIGHVY	11					HLA-B15:01	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.178	0.04	0.557	0.09490901	3.084	0.975792	-1.54804052	no	0	2.919135799116131		PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-0CQM64X89C-U	TOGZJCOT	Skin	Skin Cutaneous Melanoma	MED13	SNV	p.P1691S	6	SVQIISCQY	SVQIIPCQY	9					HLA-A30:02	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.122	2.5	0.031	0.99646705	3.044	0.965587	0.541341168	no	0	2.533189523071888		PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-8V8HWA94GP-6	TOGZJCOT	Skin	Skin Cutaneous Melanoma	MED13	SNV	p.P1691S	5	VQIISCQY	VQIIPCQY	8	17	61961773	G	A	HLA-A30:02	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	1.365	4	11.228	0.9654861	3.326	0.965587	0.328300587	no	0	2.533189523071888		PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-R8DTB8R876-H	TOGZJCOT	Skin	Skin Cutaneous Melanoma	MED13	SNV	p.P1691S	5	VQIISCQY	VQIIPCQY	8	17	61961773	G	A	HLA-B15:01	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.34	0.12	0.377	0.39582428	3.326	0.965587	0.10209787	no	0	2.533189523071888		PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-NG120S2XBY-F	TOGZJCOT	Skin	Skin Cutaneous Melanoma	MED13	SNV	p.P1691S	7	VSVQIISCQY	VSVQIIPCQY	10					HLA-A30:02	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.491	3.5	1.446	0.9920119	3.218	0.965587	-0.085822619	no	0	2.533189523071888		PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-HHJP6E4WJE-W	TOGZJCOT	Skin	Skin Cutaneous Melanoma	MED13	SNV	p.P1691S	7	VSVQIISCQY	VSVQIIPCQY	10					HLA-A01:01	CD8	"multimer, ELISPOT"	"PBMC_pre, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.715	0.12	1.623	0.058954675	3.218	0.965587	0.035590945	no	0	2.533189523071888		PMID:26901407	Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of Melanoma patients
NDDR-NS03YKG0DA-S	DYEDTPM2	Ovary	Ovarian Cancer	HLA-DRB1	SNV	p.I248L	8	FLGAGLFLYF	FLGAGLFIYF	10	6	32580767	T	G	HLA-A02:01	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	5.948	4	0.317	0.38981387	1.956	0.838477	0.003536846	no	0	8.017806688167449	Other Tumor Driver	PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-NATBNFYEAK-1	YQSS3IYL	Ovary	Ovarian Cancer	HS6ST1	SNV	p.S405I	4	DYMIHIIEKW	DYMSHIIEKW	10	2	128268184	C	A	HLA-A23:01	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	0.328	0.9	0.215	0.5965645	0.846	0.959502	0.291755398	no	0	4.582285020651232		PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-BHHDNDR6ZQ-7	VMHDDH4X	Ovary	Ovarian Cancer	COPG2	SNV	p.T37I	1	IPINPRRCL	TPINPRRCL	9	7	130666910	G	A	HLA-B07:02	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	0.025	0.06	0.434	0.80835074	0.486	0.764573	0.083381609	no	0	3.1538863840856237		PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-FQESYTA52V-C	BFEZW33V	Ovary	Ovarian Cancer	EBF4	SNV	p.I510S	2	ASMPSSPPL	AIMPSSPPL	9	20	2755627	T	G	HLA-B15:01	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	2.235	1.8	2.416	0.009759571	1.436	0.957767	0.54959901	no	0	2.825521075205641		PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-PZTTJ71JFS-9	BFEZW33V	Ovary	Ovarian Cancer	TRIM26	SNV	p.G497W	5	LDYEWGTVTF	LDYEGGTVTF	10	6	30186007	C	A	HLA-B15:01	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	4.054	5.5	0.619	0.4396839	2.696	0.975767	0.273800899	no	1	4.100178731752236		PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-1V9MW00YAR-8	BFEZW33V	Ovary	Ovarian Cancer	DCHS1	SNV	p.P141L	9	VADINDHAL	VADINDHAP	9					HLA-C03:03	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	0.078	11	0.047	0.6778647	0.722	0.050902	-5.09838002	yes	0	0.4893374088893816		PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-RABCTRZ18B-T	TKJU56TT	Ovary	Ovarian Cancer	SEPT9	SNV	p.R289H	7	SILEQMHRK	SILEQMRRK	9					HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	0.02	0.6	0.128	0.18997331	0.682		-1.848454813	no	1			PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-81PF6HAJE6-H	Q2ITNIFI	Ovary	Ovarian Cancer	PDPN	SNV	p.G222C	3	FICAIIVVV	FIGAIIVVV	9	1	13614365	G	T	HLA-A02:01	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	1.217	0.4	0.024	0.68458986	0.196	0.680153	0.893544016	no	0	2.404058397054795		PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-WAWJVEYCNM-3	Q2ITNIFI	Ovary	Ovarian Cancer	KIR2DS4	SNV	p.I7S	1	SMACVGFFL	IMACVGFFL	9					HLA-A02:01	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	1.021	1.9	0.068	0.3632761	1.164	0.623868	-0.075436319	no	0	-5.058893689053568		PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-S6WF724CZW-D	TRB3HZII	Ovary	Ovarian Cancer	HHAT	SNV	p.L75F	8	KQWLVWLFL	KQWLVWLLL	9	1	210387531	C	T	HLA-A02:06	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	1.055	5.5	0.42	0.2886589	1.67	0.883886	0.211364852	no	1	-0.3113272616608571		PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-B9FTPHZX9N-4	GNQ75CJK	Ovary	Ovarian Cancer	USP47	SNV	p.V170L	5	TSDYLSQSY	TSDYVSQSY	9	11	11892058	G	C	HLA-A01:01	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	0.002	0.4	0.004	0.25253442	2.636	0.971324	0	no	0	0.7376002403722687		PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-249DDXWAEX-E	Q2CMUUIO	Ovary	Ovarian Cancer	ZCCHC11	SNV	p.P1265H	8	GRKLFGTHF	GRKLFGTPF	9	1	52445815	G	T	HLA-B27:05	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	0.083	1	0.002	0.8584188	2.74		-1.036480508	no	0			PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-7HYKQEP4CF-X	Q2CMUUIO	Ovary	Ovarian Cancer	TP53	SNV	p.A159V	4	RVRVMAIYK	RVRAMAIYK	9	17	7675136	G	A	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	0.275	0.12	0.109	0.36357912	0.902	0.656203	0.682297165	no	1	4.5900989584528045	Other Tumor Driver	PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-P8JN2PCQXP-6	Q2CMUUIO	Ovary	Ovarian Cancer	OR2T3	SNV	p.C132Y	2	VYRPLHYPLL	VCRPLHYPLL	10	1	248473745	G	A	HLA-C07:02	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	0.997	17	0.801	0.9149756	1.256	0.853258	-0.911263069	no	0	-9.965784284662089		PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-8KVBFCA09D-V	4DKUZH62	Ovary	Ovarian Cancer	ODZ3	SNV	p.A2490V	9	GAQSWLWFV	GAQSWLWFA	9	4	182799720	C	T	HLA-A02:11	CD8	"ELISPOT, ICS, multimer"	PBMC_pre	peptide_pulsed_APC	none	0.923	0.7	0.142	0.9752533	0.216		-1.199847296	yes	0			PMID:29545564	Sensitive and frequent identification of high avidity neo-epitope specific CD8?+?T cells in immunotherapy-naive ovarian cancer
NDDR-KZ1CVJYBN3-E	65DW3BKE	Brain	Glioblastoma (GBM)	ARHGAP35	SNV	p.T1313M	1	MVNTVAGAMK	TVNTVAGAMK	10	19	46989577	C	T	HLA-A68:01	CD8	"ELISPOT, ICS"	"PBMC_postVax, patient_Tc_line"	peptide_pulsed_APC	none	0.796	0.6	0.36	0.11304907	0.424	0.576836	0.325229145	no	0	3.854868211998318	Other Tumor Driver	PMID:30568305	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
NDDR-C7G64WM1VP-6	65DW3BKE	Brain	Glioblastoma (GBM)	SLX4	SNV	p.R1814H	6	TTAATHREK	TTAATRREK	9	16	3582406	C	T	HLA-A68:01	CD8	"ELISPOT, ICS"	"PBMC_postVax, patient_Tc_line"	peptide_pulsed_APC	none	0.19	1.3	0.065	0.060915194	0.502	0.330413	-0.463402945	no	0	1.1642972325758092		PMID:30568305	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
NDDR-453FFPEY00-B	YG2NSK3U	Brain	Glioblastoma (GBM)	IDH1	SNV	p.R132H	10	GWVKPIIIGH	GWVKPIIIGR	10	2	208248388	C	T	HLA-B58:01	CD8	ICS	PBMC_postVax	peptide_pulsed_APC	none	29.107	49	20.4	0.019775497	-0.336	0.868231	-0.230243719	yes	0	5.0249227509655015	Tumor Driver	PMID:30733620	Actively personalized vaccination trial for newly diagnosed glioblastoma
NDDR-W3ZRQB9QB9-K	TBH3PNXF	Brain	Glioblastoma (GBM)	SLC44A2	SNV	p.L204M	4	ITDMVEGAKK	ITDLVEGAKK	10					HLA-A03:01	CD8	ICS	PBMC_postVax	peptide_pulsed_APC	none	2.002	2.5	1.811	0.17725703	0.114	0.373603	-0.165362037	no	0	5.438249584664644		PMID:30733620	Actively personalized vaccination trial for newly diagnosed glioblastoma
NDDR-Q35B4A9CVQ-7	MYK5YWYV	Brain	Glioblastoma (GBM)	RFX1	SNV	p.T324M	2	YMQTASTSYY	YTQTASTSYY	10					HLA-A01:01	CD8	ICS	PBMC_postVax	peptide_pulsed_APC	none	0.332	1	0.059	0.13062443	2.824	0.966927	2.22161603	no	0	1.4104223324555083		PMID:30733620	Actively personalized vaccination trial for newly diagnosed glioblastoma
NDDR-0EZ996H7KA-S	MYK5YWYV	Brain	Glioblastoma (GBM)	EPHB3	SNV	p.R677W	7	YTERQRWDF	YTERQRRDF	9					HLA-A01:01	CD8	ICS	PBMC_postVax	peptide_pulsed_APC	none	0.615	5	0.469	0.021731572	2.126	0.088796	-0.998956638	no	0	2.6118802265891805		PMID:30733620	Actively personalized vaccination trial for newly diagnosed glioblastoma
NDDR-A9KQRJ0YTC-U	ZLZLTBFT	Brain	Glioblastoma (GBM)	NUCB1	SNV	p.V300M	8	RLRMREHMMK	RLRMREHVMK	10					HLA-A03:01	CD8	ICS	PBMC_postVax	peptide_pulsed_APC	none	0.167	0.15	0.361	0.35916224	0.784	0.947325	-0.247982203	no	0	5.924214386698314		PMID:30733620	Actively personalized vaccination trial for newly diagnosed glioblastoma
NDDR-33JMV261X3-E	KZYSWBUF	Brain	Glioblastoma (GBM)	ATF7	SNV	p.R131H	1	HPGSLPLHL	RPGSLPLHL	9					HLA-B53:01	CD8	ICS	PBMC_postVax	peptide_pulsed_APC	none	0.063	1.9	0.016	0.41726562	-0.042	0.975242	-2.00533357	no	0	1.5754683550479136		PMID:30733620	Actively personalized vaccination trial for newly diagnosed glioblastoma
NDDR-GFWDJT4ZT7-I	KZYSWBUF	Brain	Glioblastoma (GBM)	EPS15	SNV	p.T217M	9	LVPPSKRKMWV	LVPPSKRKTWV	11					HLA-A68:02	CD8	ICS	PBMC_postVax	peptide_pulsed_APC	none	6.879	20	19.909	0.24659498	0.456	0.732632	-0.150092866	no	0	4.122713875214625	Other Tumor Driver	PMID:30733620	Actively personalized vaccination trial for newly diagnosed glioblastoma
NDDR-AVMMMGVYAD-V	E2RY6NVI	Brain	Glioblastoma (GBM)	PCDH19	SNV	p.A470T	6	NNTPGTYLLSV	NNTPGAYLLSV	11					HLA-A02:01	CD8	ICS	PBMC_postVax	peptide_pulsed_APC	none	26.868	18	4.418	0.20546159	0.362	0.969457	0.004887613	no	0	1.228014630177265		PMID:30733620	Actively personalized vaccination trial for newly diagnosed glioblastoma
NDDR-7CFRJFW87P-6	E2RY6NVI	Brain	Glioblastoma (GBM)	C14orf102	SNV	p.P979L	2	YLLAPLREAL	YPLAPLREAL	10					HLA-A02:01	CD8	"ICS, multimer"	PBMC_postVax	peptide_pulsed_APC	none	0.477	1.3	1.706	0.35997468	0.844		-0.984752365	no	0			PMID:30733620	Actively personalized vaccination trial for newly diagnosed glioblastoma
NDDR-44QS1THAG3-E	F3UNKL3Y	Brain	Glioblastoma (GBM)	RBKS	SNV	p.T95A	7	KQNDISAEF	KQNDISTEF	9					HLA-B15:01	CD8	ICS	PBMC_postVax	peptide_pulsed_APC	none	0.004	0.02	0.002	0.29537684	2.718	0.966161	0.287682072	no	0	0.3331357279025131		PMID:30733620	Actively personalized vaccination trial for newly diagnosed glioblastoma
NDDR-6J2G3WKA08-J	GVYOONV4	Brain	Glioblastoma (GBM)	SLC9A6	SNV	p.N572I	10	SAWLFRMWYI	SAWLFRMWYN	10					HLA-A02:01	CD8	ICS	PBMC_postVax	peptide_pulsed_APC	none	13.515	6	1.186	0.17660923	1.012	0.022848	-1.778226455	no	0	2.120798798361302		PMID:30733620	Actively personalized vaccination trial for newly diagnosed glioblastoma
NDDR-EDQDWAWTP4-F	PFMINZ56	Breast	Breast Cancer	ECPAS	SNV	p.S186F	10	MPYGYVLNEF	MPYGYVLNES	10	9	111437072_111437073	CA	TT	HLA-B35:01	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.056	0.05	0.018	0.47865343	2.356	0.422068	-4.303582351	yes	0	4.401606288396909		PMID:29867227	Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
NDDR-Y3TJTRGEMA-S	PFMINZ56	Breast	Breast Cancer	CADPS2	SNV	p.R1266H	8	TYDTVHRHL	TYDTVHRRL	9	7	122320259	C	T	HLA-C04:01	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.006	25	0.001	0.66004187	0.732	0.958242	-0.287682072	no	0	3.089786043720456		PMID:29867227	Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
NDDR-9MF2CZ9EEC-U	6TP4IBLE	Skin	Skin Cutaneous Melanoma	PORCN	SNV	p.H346Y	8	LLHGFSFYL	LLHGFSFHL	9	X	48515902	C	T	HLA-A02:01	CD8	"multimer, 51Cr"	"PBMC_pre, PBMC_postVax, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.086	0.15	0.015	0.73443514	1.068	0.977941	0.059898142	no	1	1.8863837225668296		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-7HFGTRT2KG-Y	6TP4IBLE	Skin	Skin Cutaneous Melanoma	AKAP9	SNV	p.L947F	5	RLSDFSEQL	RLSDLSEQL	9	7	92002801	C	T	HLA-A02:01	CD8	"multimer, 51Cr"	"PBMC_pre, PBMC_postVax, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.024	0.4	0.069	0.49961323	1.168	0.977036	-0.223143551	no	1	2.05500471197816	Other Tumor Driver	PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-R6WWVF6EQ6-H	6TP4IBLE	Skin	Skin Cutaneous Melanoma	RASAL2	SNV	p.P637S	4	IMSSSLFNL	IMSPSLFNL	9	1	178452552	C	T	HLA-A02:01	CD8	multimer	"PBMC_pre, PBMC_postVax, patient_TIL"	peptide_pulsed_APC	none	0.236	0.6	0.066	0.30667874	1.032	0.969002	1.352957941	no	1	1.3316192229287085		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-108MYSE1VC-U	6TP4IBLE	Skin	Skin Cutaneous Melanoma	CDKN2A	SNV	p.P114L	2	LLVDLAEEL	LPVDLAEEL	9	9	21971018	G	A	HLA-A02:01	CD8	multimer	"PBMC_pre, PBMC_postVax, patient_TIL"	peptide_pulsed_APC	none	0.1	2.5	0.174	0.4786835	1.164	0.957983	-4.712319102	no	0	1.258458621457592	Tumor Driver	PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-1G2Z2Z3NBX-E	6TP4IBLE	Skin	Skin Cutaneous Melanoma	PDE7B	SNV	p.G113R	1	RMWDFDIFL	GMWDFDIFL	9	6	136149105	G	A	HLA-A02:01	CD8	multimer	"PBMC_pre, PBMC_postVax, patient_TIL"	peptide_pulsed_APC	none	0.022	0.09	0.005	0.7197922	1.63	0.968043	-0.127833372	no	0	-1.260168451057003		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-SEA7CN1KAX-E	6TP4IBLE	Skin	Skin Cutaneous Melanoma	GCN1L1	SNV	p.P274L	6	SLLRSLENV	SLLRSPENV	9	12	120177464	G	A	HLA-A02:01	CD8	"multimer, 51Cr"	"PBMC_pre, PBMC_postVax, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.06	0.4	0.081	0.54666144	0.416		-0.559615788	no	1			PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-EZBD3HKP1K-1	6TP4IBLE	Skin	Skin Cutaneous Melanoma	SOCS6	SNV	p.P134L	9	SLRSHHYSL	SLRSHHYSP	9	18	70325069	C	T	HLA-B08:01	CD8	"multimer, 51Cr"	"PBMC_pre, PBMC_postVax, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.006	0.6	0.023	0.48079756	1.118	0.409931	-5.37296091	yes	1	3.0672944671553912		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-5GDBWJVZ1H-Z	6TP4IBLE	Skin	Skin Cutaneous Melanoma	POGK	SNV	p.P46L	3	WVLALFDEV	WVPALFDEV	9	1	166846616	C	T	HLA-A02:01	CD8	multimer	"PBMC_pre, PBMC_postVax, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	none	3.02	4.5	0.733	0.34715846	0.314	0.288239	-0.050995237	no	0	3.563060296867492		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-T0AFTDJ9PD-V	6TP4IBLE	Skin	Skin Cutaneous Melanoma	ZDBF2	SNV	p.S2228L	3	YILKYSVFL	YISKYSVFL	9	2	206311211	C	T	HLA-A02:01	CD8	"multimer, 51Cr"	"PBMC_pre, PBMC_postVax, patient_TIL"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.193	0.5	0.027	0.61301035	0.96	0.963955	-0.179727522	no	1	-0.664534160245007		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-47041KC807-I	6TP4IBLE	Skin	Skin Cutaneous Melanoma	GAS7	SNV	p.S270F	1	FLGEAWAQV	SLGEAWAQV	9	17	9934242	G	A	HLA-A02:01	CD8	multimer	"PBMC_pre, PBMC_postVax, patient_TIL"	peptide_pulsed_APC	none	0.055	0.9	0.392	0.5921987	-0.264	0.969671	-0.828948722	no	0	5.458258899654696		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-JV00FYYZJR-8	6TP4IBLE	Skin	Skin Cutaneous Melanoma	PNPLA4	SNV	p.P100S	3	ILSPSAHEL	ILPPSAHEL	9	X	7921826	G	A	HLA-A02:01	CD8	multimer	"PBMC_pre, PBMC_postVax, patient_TIL"	peptide_pulsed_APC	none	0.024	1.4	0.196	0.43104225	0.922	0.976745	-0.432864082	no	0	2.4620915882703924		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-F4XKDRRJHC-U	OHRF7YEV	Skin	Skin Cutaneous Melanoma	SIPA1L3	SNV	p.S893F	5	ILGIFNEFV	ILGISNEFV	9	19	38119692	C	T	HLA-A02:01	CD8	multimer	"PBMC_pre, PBMC_postVax, patient_TIL"	peptide_pulsed_APC	none	0.531	1.2	0.207	0.5177895	-0.036	0.159378	-0.479842078	no	1	1.747236986219996		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-ENN0NBG9ZX-E	OHRF7YEV	Skin	Skin Cutaneous Melanoma	ERCC6L	SNV	p.V476I	7	KIYRRQIFK	KIYRRQVFK	9	X	72206972	C	T	HLA-A11:01	CD8	multimer	"PBMC_pre, PBMC_postVax, patient_TIL"	peptide_pulsed_APC	none	0.037	0.12	0.193	0.35617954	1.114	0.56284	-0.150282203	no	1	0.1825635636652645		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-N9MR011VMC-U	OHRF7YEV	Skin	Skin Cutaneous Melanoma	RUFY1	SNV	p.K225N	7	KLADYLNVL	KLADYLKVL	9	5	179567533	A	C	HLA-A02:01	CD8	multimer	"PBMC_pre, PBMC_postVax, patient_TIL"	peptide_pulsed_APC	none	0.028	0.5	0.004	0.7603814	1.148	0.836973	-0.810930216	no	1	3.023272193793606		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-236NEQ2JD9-K	OHRF7YEV	Skin	Skin Cutaneous Melanoma	SMARCC2	SNV	p.S624F	3	KVFEHVGSR	KVSEHVGSR	9	12	56171900	G	A	HLA-A11:01	CD8	multimer	"PBMC_pre, PBMC_postVax, patient_TIL"	peptide_pulsed_APC	none	0.115	0.8	0.138	0.23685719	1.986	0.619811	-1.020258974	no	1	3.362729351790902		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-DA4VS975F2-D	OHRF7YEV	Skin	Skin Cutaneous Melanoma	MPV17	SNV	p.R75G	4	VLDGFIPGT	VLDRFIPGT	9	2	27312736	G	C	HLA-A02:01	CD8	multimer	"PBMC_pre, PBMC_postVax, patient_TIL"	peptide_pulsed_APC	none	0.548	5	0.216	0.3754542	-1.006	0.059142	-0.840496893	no	1	3.887417648096396		PMID:31685621	Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens
NDDR-N6NTA1JDTE-W	352WTYXA	Ovary	Ovarian Cancer	PPM1F	SNV	p.C259Y	7	FLAPLFLVLL	FLAPLFCVLL	10	5	88203038	T	G	HLA-A24:02	CD8	ELISPOT	"PBMC_postVax, patient_TIL"	peptide_pulsed_APC	none	8.36	3	1.457	0.027011096	0.736		-0.252377128	no	0	0.7803940963093237		PMID:32660279	Intranodal Administration of Neoantigen Peptide-loaded Dendritic Cell Vaccine Elicits Epitope-specific T Cell Responses and Clinical Effects in a Patient with Chemorefractory Ovarian Cancer with Malignant Ascites
NDDR-MCK2ZAJ8GQ-7	R7NU4BAT	Brain	Glioblastoma (GBM)	WDR63	SNV	p.T690M	8	FYNDIILMV	FYNDIILTV	9	1	85124208	C	T	HLA-C06:02	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	none	0.042	34	0.001	0.93794346	0.026		0.518793793	no	0			PMID:30906654	Detection of neoantigen-specific T cells following a personalized vaccine in a patient with glioblastoma
NDDR-NWMYCN5E92-D	X3AIF5LA	Head & Neck	Head and Neck Squamous Cell Carcinoma	MAGOHB	SNV	p.G17A	8	RYYVGHKAKF	RYYVGHKGKF	10	12	10613483	C	G	HLA-A24:02	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.097	0.25	0.327	0.5310621	3.282	0.650931	-0.850239039	no	0	1.530218260762219		PMID:30906664	Identification of neoantigen-specific T cells and their targets: Implications for immunotherapy of head and neck squamous cell carcinoma
NDDR-S6DN480CYD-V	XD6MQQ3M	Ovary	Ovarian Cancer	SSC4D	SNV	p.D85Y	9	YGTGHILLY	YGTGHILLD	9	7	76397626	C	A	HLA-B35:01	CD8	"4-1BB, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells"	none	0.347	5	0.095	0.34794	2.496	0.067292	-5.180179441	yes	0	1.2413520857706586		PMID:31069153	Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
NDDR-VS85BXHK0E-W	XD6MQQ3M	Ovary	Ovarian Cancer	SSC4D	SNV	p.D85Y	9	YGTGHILLY	YGTGHILLD	9	7	76397626	C	A	HLA-C12:03	CD8	"4-1BB, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells"	none	0.117	18	0.008	0.0625905	2.496	0.067292	-5.774365724	yes	0	1.2413520857706586		PMID:31069153	Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
NDDR-HR56JF3PKD-V	XD6MQQ3M	Ovary	Ovarian Cancer	NAV1	SNV	p.K349M	1	MAKAKAVAL	KAKAKAVAL	9					HLA-B35:01	CD8	"4-1BB, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells"	none	0.841	1.2	1.189	0.061466467	1.048	0.941944	-1.781601031	yes	0	0.4814022827632454		PMID:31069153	Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
NDDR-C5YZS7EBSD-V	XD6MQQ3M	Ovary	Ovarian Cancer	TRO	SNV	p.S598C	5	SVGACGFSY	SVGASGFSY	9	X	54930991	C	G	HLA-B35:01	CD8	"4-1BB, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells"	none	1.793	2.5	0.289	0.02986968	2.782		1.156591222	yes	0	1.6029319040696397		PMID:31069153	Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
NDDR-1V4ASC67M4-F	XD6MQQ3M	Ovary	Ovarian Cancer	CLEC10A	SNV	p.V143F	1	FPVHSEMLL	VPVHSEMLL	9	17	7076078	C	A	HLA-B35:01	CD8	"4-1BB, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells"	none	0.108	0.05	0.222	0.65602815	0.276	0.904387	-1.504077397	yes	0	-1.426237704423677		PMID:31069153	Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
NDDR-DHRA9GQ79C-U	XD6MQQ3M	Ovary	Ovarian Cancer	DDX60L	SNV	p.V257G	7	YVIFDEGHY	YVIFDEVHY	9	4	168416796	A	C	HLA-A25:01	CD8	"4-1BB, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells"	none	0.176	0.7	1.467	0.009464866	3.034	0.960788	0.40831006	no	0	0.3201958212661251		PMID:31069153	Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
NDDR-4JRXXBJTP9-K	XD6MQQ3M	Ovary	Ovarian Cancer	DDX60L	SNV	p.V257G	7	YVIFDEGHY	YVIFDEVHY	9	4	168416796	A	C	HLA-A26:03	CD8	"4-1BB, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells"	none	0.207	2.5	0.243	0.002461469	3.034	0.960788	0.659889959	no	0	0.3201958212661251		PMID:31069153	Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
NDDR-1NET55E0BS-9	XD6MQQ3M	Ovary	Ovarian Cancer	OR51B4	SNV	p.K183N	1	NLACADITF	KLACADITF	9	11	5301398	T	G	HLA-B35:01	CD8	"4-1BB, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells"	none	1.629	5.5	0.174	0.05186329	2.808	0.467745	-0.909515221	yes	0	-9.965784284662089		PMID:31069153	Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer
NDDR-C2M6EQ7T1C-U	3N22S6UG	Pleura/Peritoneum (Mesothelium)	Mesothelioma	ROBO3	SNV	p.P640H	3	SEHSPVSEPV	SEPSPVSEPV	10	11	124874204	C	A	HLA-B49:01	CD8	"ELISPOT, multimer"	"patient_TIL, TCR_clone"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.123	0.4	1.985	0.000896022	0.454	0.978091	-1.310308454	no	0	1.7775775222037775		PMID:32002298	Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma
NDDR-K2DC19WSYP-6	XR365KHL	Colon/Rectum	Colorectal Adenocarcinoma	AP2S1	SNV	p.N86K	8	AYLEAIHKF	AYLEAIHNF	9	19	46839474	G	C	HLA-A24:02	CD8	"ELISPOT, 4-1BB, multimer"	"PBMC_pre, TCR_clone"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.001	0.01	0.004	0.6267046	2.988	0.9139	0	no	1	5.890231347157432		PMID:33537174	Characterization of CD8+ T-cell responses to non-anchor-type HLA class I neoantigens with single amino-acid substitutions
NDDR-W656ADT8F2-D	E2RCTTBH	Colon/Rectum	Colorectal Adenocarcinoma	RAD21	SNV	p.D116E	8	TLPEEFHEF	TLPEEFHDF	9	20	1231599	T	G	HLA-A24:02	CD8	"ELISPOT, 4-1BB, multimer"	"PBMC_pre, TCR_clone"	"peptide_pulsed_APC, TMC_minigene"	TMC	0.071	1.3	0.099	0.3135603	2.482	0.97333	-1.126391853	no	1	5.328211178598163	Other Tumor Driver	PMID:33537174	Characterization of CD8+ T-cell responses to non-anchor-type HLA class I neoantigens with single amino-acid substitutions
NDDR-R26MH0CSKN-4	CNMRPXNS	Skin	Skin Cutaneous Melanoma	CTNNB1	SNV	p.S37F	9	SYLDSGIHF	SYLDSGIHS	9	3	41224622	C	T	HLA-A24:02	CD8	51Cr	"patient_TIL, TCR_clone"	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.005	0.15	0.019	0.42225286	2.788	0.297074	-6.658524393	no	1	6.145806838558247	Tumor Driver	PMID:8642260	A mutated beta-catenin gene encodes a Melanoma-specific antigen recognized by tumor infiltrating lymphocytes
NDDR-37B57SH6R0-B	TUR5WXAA	Brainstem	Diffuse Intrinsic Pontine Glioma (DIPG)	H3.3	SNV	p.K27M	2	RMSAPSTGGV	RKSAPSTGGV	10					HLA-A02:01	CD8	"ELISPOT, multimer"	"PBMC_pre, TCR_clone"	"peptide_pulsed_APC, TMC_minigene"	endogenous(HLA-block)	3.181	2.5	4.599	0.1890224	0.638		-1.803479269	no	1			PMID:29203539	Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy
NDDR-45BGP1PWVE-W	TSCSRBJX	Lung	Non-Small Cell Lung Cancer (NSCLC)	HERC1	SNV	p.P3278S	5	ASNASSAAK	ASNAPSAAK	9	15	63656126	G	A	HLA-A11:01	CD8	multimer	PBMC_pre	NA	none	0.063	0.2	0.202	0.016285526	0.628	0.757075	1.435084525	no	1	1.661703880118977		PMID:25765070	Mutational landscape determines sensitivity to PD-1 blockade in Non-Small Cell Lung Cancer
NDDR-ZZCXMGS11K-1	I7RVCSQA	Skin	Skin Cutaneous Melanoma	TKT	SNV	p.R438W	4	AMFWSVPTV	AMFRSVPTV	9					HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	endogenous(HLA-block)	0.048	0.06	0.049	0.6563868	0.914		0.613104473	no	1	5.450839799211661		PMID:25837513	A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells
NDDR-EG72WSWBJ2-D	I7RVCSQA	Skin	Skin Cutaneous Melanoma	TMEM48	SNV	p.F169L	9	CLNEYHLFL	CLNEYHLFF	9	1	53825887	A	G	HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	endogenous(HLA-block)	0.471	0.7	0.02	0.63726187	0.71		-2.357925389	no	1			PMID:25837513	A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells
NDDR-XS0VMV497T-A	I7RVCSQA	Skin	Skin Cutaneous Melanoma	CDKN2A	SNV	p.E153K	1	KMIGNHLWV	EMIGNHLWV	9	9	21970902	C	T	HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	endogenous(HLA-block)	0.367	1.2	0.251	0.48655686	0.722		-2.239897718	no	1	1.258458621457592	Tumor Driver	PMID:25837513	A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells
NDDR-VZY3AW8E59-K	OHQJPMZB	Skin	Skin Cutaneous Melanoma	MRPS5	SNV	p.P59L	2	HLYASLSRA	HPYASLSRA	9					HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	endogenous(HLA-block)	0.473	0.7	1.265	0.37619278	-0.25	0.772974	-3.771034095	no	0	2.6318840895149616		PMID:25837513	A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells
NDDR-K689FMSYGB-T	OHQJPMZB	Skin	Skin Cutaneous Melanoma	EXOC8	SNV	p.Q656P	7	IILVAVPHV	IILVAVQHV	9	1	231335779	T	G	HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	endogenous(HLA-block)	0.269	0.8	0.135	0.51179826	0.442	0.914216	-0.695004191	no	1	2.0087179035446807		PMID:25837513	A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells
NDDR-R0G5X7EEK3-E	OHQJPMZB	Skin	Skin Cutaneous Melanoma	PABPC1	SNV	p.R520Q	5	MLGEQLFPL	MLGERLFPL	9	13	25097877	G	A	HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	endogenous(HLA-block)	0.155	0.3	0.259	0.3916106	0.658	0.885752	-0.331853291	no	1	7.21061634113286	Other Tumor Driver	PMID:25837513	A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells
NDDR-SNZZ9WV27P-6	LE64IB2Z	Skin	Skin Cutaneous Melanoma	SEC24A	SNV	p.P469L	5	FLYNLLTRV	FLYNPLTRV	9	5	134682397	C	T	HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	endogenous(HLA-block)	0.011	0.02	0.005	0.8063054	0.436	0.97348	0.78845736	no	1	2.349832322010078		PMID:25837513	A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells
NDDR-Q70W8H7WCX-E	LE64IB2Z	Skin	Skin Cutaneous Melanoma	AKAP13	SNV	p.Q285K	8	KLMNIQQKL	KLMNIQQQL	9	15	85575321	C	A	HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	endogenous(HLA-block)	0.018	0.5	0.087	0.3996232	1.244	0.955397	0.587786665	no	1	2.2593611179809745		PMID:25837513	A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells
NDDR-66X9B58J2S-9	LE64IB2Z	Skin	Skin Cutaneous Melanoma	OR8B3	SNV	p.T190I	5	QLSCISTYV	QLSCTSTYV	9	11	124396783	G	A	HLA-A02:01	CD8	"ELISPOT, ICS"	PBMC_postVax	peptide_pulsed_APC	endogenous(HLA-block)	0.805	0.7	0.037	0.5697854	0.166	0.819139	-0.695008801	no	1	-9.965784284662089		PMID:25837513	A dendritic cell vaccine increases the breadth and diversity of Melanoma neoantigen-specific T cells
NDDR-8SEE5W52XN-4	ASV5ARII	Colon/Rectum	Colorectal Adenocarcinoma	CASP8	SNV	p.F67V	4	ELLVRINRL	ELLFRINRL	9					HLA-B08:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	"peptide_pulsed_APC, TMC_minigene"	TMC	0.018	2.5	0.024	0.31329224	0.614	0.934579	-0.635988767	yes	0	2.5103543088155917	Other Tumor Driver	PMID:26516200	Immunogenicity of somatic mutations in human Colorectal Cancers
NDDR-XMJTSB7ZM1-C	ABT5UFIF	Colon/Rectum	Colorectal Adenocarcinoma	KRAS	SNV	p.G12D	3	GADGVGKSAL	GAGGVGKSAL	10					HLA-C05:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	"peptide_pulsed_APC, TMC_minigene"	TMC	0.409	17	0.627	0.15130626	0.568	0.438231	-3.503668642	no	1	2.9917856922921353	Tumor Driver	PMID:26516200	Immunogenicity of somatic mutations in human Colorectal Cancers
NDDR-GGQCET69F7-I	ABT5UFIF	Colon/Rectum	Colorectal Adenocarcinoma	KRAS	SNV	p.G12D	3	GADGVGKSAL	GAGGVGKSAL	10					HLA-C08:02	CD8	"ELISPOT, 4-1BB"	patient_TIL	"peptide_pulsed_APC, TMC_minigene"	TMC	0.171	15	0.17	0.18107818	0.568	0.438231	-4.094344562	no	1	2.9917856922921353	Tumor Driver	PMID:26516200	Immunogenicity of somatic mutations in human Colorectal Cancers
NDDR-1PCSWDWSSK-1	FFRFFTSB	Colon/Rectum	Colorectal Adenocarcinoma	SKIV2L	SNV	p.R653H	6	EMLFSHGLVK	EMLFSRGLVK	10					HLA-A03:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	"peptide_pulsed_APC, TMC_minigene"	TMC	0.672	3	0.997	0.08092839	0.234		-0.221952366	no	0	3.394047590132866		PMID:26516200	Immunogenicity of somatic mutations in human Colorectal Cancers
NDDR-S8SEJXG8AF-X	FFRFFTSB	Colon/Rectum	Colorectal Adenocarcinoma	SKIV2L	SNV	p.R653H	5	MLFSHGLVK	MLFSRGLVK	9					HLA-A03:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	"peptide_pulsed_APC, TMC_minigene"	TMC	0.011	0.12	0.031	0.18879895	0.718		-0.435318071	no	0	3.394047590132866		PMID:26516200	Immunogenicity of somatic mutations in human Colorectal Cancers
NDDR-B97ZRMVPRV-C	Q5EFISOX	Colon/Rectum	Colorectal Adenocarcinoma	PHLPP1	SNV	p.G566E	4	ILCETCLIV	ILCGTCLIV	9	18	62830155	G	A	HLA-A02:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	"peptide_pulsed_APC, TMC_minigene"	TMC	1.593	0.25	0.118	0.5297906	0.308	0.944836	-0.571472401	no	1	1.3514587222137173		PMID:26516200	Immunogenicity of somatic mutations in human Colorectal Cancers
NDDR-QTM9DE22BE-W	Q5EFISOX	Colon/Rectum	Colorectal Adenocarcinoma	API5	SNV	p.R243Q	6	LLQCTQQAV	LLQCTRQAV	9					HLA-A02:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	"peptide_pulsed_APC, TMC_minigene"	TMC	1.596	1.2	0.781	0.29171476	0.304	0.168038	-0.839209383	no	0	4.559004648541702		PMID:26516200	Immunogenicity of somatic mutations in human Colorectal Cancers
NDDR-HNTCR16H6A-S	Q5EFISOX	Colon/Rectum	Colorectal Adenocarcinoma	API5	SNV	p.R243Q	7	RLLQCTQQAV	RLLQCTRQAV	10					HLA-A02:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	"peptide_pulsed_APC, TMC_minigene"	TMC	1.056	0.15	1.857	0.121157765	0.572	0.168038	-0.691725716	no	0	4.559004648541702		PMID:26516200	Immunogenicity of somatic mutations in human Colorectal Cancers
NDDR-ABZZYTEMDY-F	CUZXO5J4	Pancreas	Pancreatic Adenocarcinoma (PDAC)	ZFYVE27	SNV	p.R6H	2	EHEGSGPEL	EREGSGPEL	9					HLA-B38:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	"peptide_pulsed_APC, TMC_minigene"	TMC	0.012	13	0.077	0.080678545	0.242	0.965456	-2.746201967	no	0	3.5900749987919154		PMID:26516200	Immunogenicity of somatic mutations in human Colorectal Cancers
NDDR-SJKB4RNY1P-6	CUZXO5J4	Pancreas	Pancreatic Adenocarcinoma (PDAC)	ZFYVE27	SNV	p.R6H	3	SEHEGSGPEL	SEREGSGPEL	10					HLA-B38:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	"peptide_pulsed_APC, TMC_minigene"	TMC	0.076	4	8.662	0.00375491	1.094	0.965456	-2.584990108	no	0	3.5900749987919154		PMID:26516200	Immunogenicity of somatic mutations in human Colorectal Cancers
NDDR-58EN4WZN3K-1	DRAI56NY	Lung	Non-Small Cell Lung Cancer (NSCLC)	MTFR2	SNV	p.D283Y	6	FAFQEYDSF	FAFQEDDSF	9	6	136233393	C	A	HLA-B35:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.071	1.1	0.055	0.5672879	2.574	0.505318	-0.106767975	yes	0	1.1642391077872483		PMID:26940869	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
NDDR-8SSFF6Q7MD-V	JHK3ND2A	Lung	Non-Small Cell Lung Cancer (NSCLC)	CHTF18	SNV	p.L351V	5	LLLDIVAPK	LLLDILAPK	9	16	793207	C	G	HLA-A11:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.552	0.4	0.188	0.21507737	0.554	0.930052	-0.09333194	no	0	1.81913615064278		PMID:26940869	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
NDDR-DZ1AEM5MX5-G	JHK3ND2A	Lung	Non-Small Cell Lung Cancer (NSCLC)	MYADM	SNV	p.R30W	9	SPMIVGSPW	SPMIVGSPR	9	19	53873617	C	T	HLA-B07:02	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.316	0.6	0.719	0.5504699	0.498	0.960977	-1.708767621	no	0	4.112007514695531		PMID:26940869	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
NDDR-HK59W4KGF1-C	WHG2YFVM	Skin	Skin Cutaneous Melanoma	GCN1L1	SNV	p.L2330P	6	ALLETPSLL	ALLETLSLL	9	12	120136521	A	G	HLA-A02:01	CD8	"multimer, ELISPOT"	PBMC_pre	TMC_minigene	none	0.045	1.3	0.048	0.54578054	1.256		0.223143551	no	0			PMID:27198675	Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
NDDR-B31HC61QZZ-G	WHG2YFVM	Skin	Skin Cutaneous Melanoma	GCN1L1	SNV	p.L2330P	6	ALLETPSLLL	ALLETLSLLL	10	12	120136521	A	G	HLA-A02:01	CD8	"multimer, ELISPOT"	PBMC_pre	TMC_minigene	none	0.154	1.3	0.143	0.30405095	1.256		-0.464305608	no	1			PMID:27198675	Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
NDDR-5EN6GMHBB6-H	WHG2YFVM	Skin	Skin Cutaneous Melanoma	CDK4	SNV	p.R71L	2	ALDPHSGHFV	ARDPHSGHFV	10	12	57751647	C	A	HLA-A02:01	CD8	"multimer, ELISPOT"	PBMC_pre	TMC_minigene	none	0.085	1.2	0.065	0.4697877	0.228	0.668099	-4.919637372	no	1	4.89146952891671	Tumor Driver	PMID:27198675	Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
NDDR-CYCDC4BR97-I	WHG2YFVM	Skin	Skin Cutaneous Melanoma	DNAH17	SNV	p.H8302Y	9	VLFEDAVAY	VLFEDAVAH	9	17	78475445	G	A	HLA-B15:01	CD8	"multimer, ELISPOT"	PBMC_pre	TMC_minigene	none	0.019	0.07	0.022	0.2762412	3.2	0.131474	-4.076644985	no	0	-3.134162571958985		PMID:27198675	Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
NDDR-NTP91MW8Y6-H	7TRJS5PW	Skin	Skin Cutaneous Melanoma	BRWD1	SNV	p.R925W	8	KPKKENLWRM	KPKKENLRRM	10	21	39232492	G	A	HLA-B07:02	CD8	"multimer, ELISPOT"	PBMC_pre	TMC_minigene	none	0.459	0.2	1.201	0.37370968	-0.122	0.278546	0.105602617	no	0	1.1671330737904817		PMID:27198675	Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
NDDR-YFVCRQNZKS-9	7TRJS5PW	Skin	Skin Cutaneous Melanoma	PARG	SNV	p.Y427N	7	ELMRDINSM	ELMRDIYSM	9	10	49820207	A	T	HLA-B35:01	CD8	"multimer, ELISPOT"	PBMC_pre	TMC_minigene	none	1.031	9.5	1.963	0.25263783	0.058	0.880625	0.166348928	yes	0	1.9625489996545604		PMID:27198675	Targeting of cancer neoantigens with donor-derived T cell receptor repertoires
NDDR-5M206ARJMA-S	G3MJINSO	Cervix	Cervical Carcinoma (HPV+)	ALDH1A1	SNV	p.N150I	6	IPIDGIFFTY	IPIDGNFFTY	10					HLA-B35:01	CD8	CD107a	patient_TIL	"TMC_minigene, peptide_pulsed_APC"	none	0.017	0.03	0.004	0.67217404	2.456	0.977859	0.060624622	yes	0	2.8478282313603214		PMID:28408606	Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
NDDR-SY7527TDDR-8	G3MJINSO	Cervix	Cervical Carcinoma (HPV+)	METTL17	SNV	p.E279K	3	RTKVVQTLW	RTEVVQTLW	9	14	20994860	G	A	HLA-A32:01	CD8	CD107a	patient_TIL	"TMC_minigene, peptide_pulsed_APC"	none	0.015	0.01	0.037	0.22831242	1.128	0.940368	-1.866660777	no	0	2.8572511252854564		PMID:28408606	Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
NDDR-TPTWEFDEXD-V	G3MJINSO	Cervix	Cervical Carcinoma (HPV+)	SETDB1	SNV	p.E21D	5	VESEDIAEL	VESEEIAEL	9	1	150927777	G	C	HLA-B40:01	CD8	CD107a	patient_TIL	"TMC_minigene, peptide_pulsed_APC"	none	0.023	0.3	0.023	0.26135123	1.012	0.963706	0.245122458	no	0	1.9320599329227528	Other Tumor Driver	PMID:28408606	Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
NDDR-XJPM5HK7FN-4	EXWFDAWT	Blood/Bone marrow	Leukemia	PLCD3	SNV	p.D314H	5	LMTLHGFMMY	LMTLDGFMMY	10	17	45118466	C	G	HLA-A30:02	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	1.197	2.5	0.376	0.9905976	3.016	0.978922	0.783124903	no	0	-0.0357862220530606		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-DCNJ84M5D6-H	EXWFDAWT	Blood/Bone marrow	Leukemia	PLCD3	SNV	p.D314H	4	MTLHGFMMY	MTLDGFMMY	9	17	45118466	C	G	HLA-A30:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	1.854	14	0.206	0.8741233	3.016	0.978922	0.123259167	no	0	-0.0357862220530606		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-CYHGXP9VS1-C	EXWFDAWT	Blood/Bone marrow	Leukemia	PLCD3	SNV	p.D314H	4	MTLHGFMMY	MTLDGFMMY	9	17	45118466	C	G	HLA-A30:02	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.124	1.1	0.061	0.9972703	3.016	0.978922	1.131402111	no	0	-0.0357862220530606		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-3C01ZQFFQT-A	KX6Z6VLS	Blood/Bone marrow	Leukemia	MCTP1	SNV	p.R783H	5	IRMKHCVMV	IRMKRCVMV	9	5	94868421	C	T	HLA-C07:02	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	1.191	13	0.984	0.25567743	0.732	0.406404	-0.509313146	no	0	2.345595080031881		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-BPHQDRGQM2-D	VTEIFCU7	Blood/Bone marrow	Leukemia	SPATA5	SNV	p.S812C	6	KLQFHCMPV	KLQFHSMPV	9	4	123256110	C	G	HLA-A02:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	1.353	0.07	0.517	0.32274988	0.41		1.121034753	no	0	1.2577951343833695		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-7GF9E27P3J-0	D3NMWBFW	Blood/Bone marrow	Leukemia	GPR139	SNV	p.A298T	2	ATTLKAFFK	AATLKAFFK	9	16	20031905	C	T	HLA-A03:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.246	0.25	0.068	0.4999201	0.684	0.574528	-1.437790887	no	0	-9.965784284662089		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-ST51E6YP0B-T	D3NMWBFW	Blood/Bone marrow	Leukemia	GPR139	SNV	p.A298T	6	RTMAATTLK	RTMAAATLK	9	16	20031905	C	T	HLA-A03:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.014	0.01	0.014	0.6425206	0.842	0.502898	-0.405465108	no	0	-9.965784284662089		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-Q1K8PG6J2Z-G	G33NW4LL	Blood/Bone marrow	Leukemia	ATP13A4	SNV	p.L109F	3	HPFMTDEEY	HPLMTDEEY	9	3	193502549	G	A	HLA-B35:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.004	0.03	0.004	0.80949837	2.478	0.619438	-0.693147181	yes	0	-2.571750389294305		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-Y9RZGDTEDJ-0	G33NW4LL	Blood/Bone marrow	Leukemia	SLC6A7	SNV	p.R62C	6	LGNVWCFPY	LGNVWRFPY	9	X	116437922_116437924	AGA	TGT	HLA-B35:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	6.302	2	1.455	0.338483	2.58	0.924153	0.427444015	yes	0	-6.9839316313723465		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-7VCA888E87-I	G33NW4LL	Blood/Bone marrow	Leukemia	ASXL3	SNV	p.E1718K	5	SPMEKAISL	SPMEEAISL	9	18	33745000	G	A	HLA-B35:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.077	0.5	0.146	0.4495259	0.568	0.967474	0.582605306	yes	0	-8.20024953829911		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-NKSNK60CB6-H	G33NW4LL	Blood/Bone marrow	Leukemia	DTX3L	SNV	p.D141H	3	TAHLNCNLF	TADLNCNLF	9	3	122568510	G	C	HLA-B35:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.678	2.5	0.606	0.30075976	2.64	0.941967	-0.188936796	yes	0	4.171647192192975		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-KS17EZFBT2-D	M2ABZXMV	Blood/Bone marrow	Leukemia	CD101	SNV	p.S889F	9	HLHCYRSSF	HLHCYRSSS	9	1	117025746	C	T	HLA-B15:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.575	1	0.19	0.24389473	2.506	0.028623	-3.756944359	no	0	0.4464679860973253		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-VF8W5J2PV2-D	M2ABZXMV	Blood/Bone marrow	Leukemia	TMEM104	SNV	p.V281I	6	LFGVCIYSF	LFGVCVYSF	9	17	74836037	G	A	HLA-A24:02	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.907	0.5	0.042	0.17712702	2.37	0.806016	0.00331309	no	0	3.3255878943110875		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-B42P9N7VWT-A	M2ABZXMV	Blood/Bone marrow	Leukemia	FAM157B	SNV	p.L156F	2	RFLHDLHLL	RLLHDLHLL	9					HLA-A24:02	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.146	0.6	0.017	0.2591804	1.32	0.875295	-2.290179696	no	0	-3.255666652618641		PMID:31243155	Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8?+?T cell responses
NDDR-KJVBD2731B-T	5VPZ7ZNO	Kidney	Collecting Duct Carcinoma	SLC27A3	SNV	p.Y704C	8	FLQEVNVCGV	FLQEVNVYGV	10					HLA-A02:03	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	none	0.313	0.07	0.482	0.3850943	-0.002	0.643552	0.269739639	no	0			PMID:32439798	Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report
NDDR-BYMHBVR7MN-4	5VPZ7ZNO	Kidney	Collecting Duct Carcinoma	KRAS	SNV	p.G12D	8	KLVVVGADGV	KLVVVGAGGV	10	12	25245350	C	T	HLA-A02:03	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	none	3.298	1.7	8.407	0.1703924	0.63	0.35561	0.029852963	no	0		Other Tumor Driver	PMID:32439798	Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report
NDDR-PHW5551Z24-F	5VPZ7ZNO	Kidney	Collecting Duct Carcinoma	DHX29	SNV	p.V1219E	5	LLKAELVAGL	LLKAVLVAGL	10	5	55262802	A	T	HLA-A02:03	CD8	ELISPOT	PBMC_postVax	peptide_pulsed_APC	none	0.853	1.7	0.961	0.30452138	1.004	0.247439	-1.000993859	no	0			PMID:32439798	Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case report
NDDR-G1RSZ7MRBS-9	GTFUJIR3	Skin	Skin Cutaneous Melanoma	WDR1	SNV	p.N544K	10	DSFAGKGHTK	DSFAGKGHTN	10	4	10083120	G	C	HLA-A68:01	CD8	multimer	patient_TIL	"tumor_cells, peptide_pulsed_APC"	none	0.178	2	0.14	0.17912829	0.454	0.073674	-5.058176239	no	0	5.888243884763167		PMID:32753545	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
NDDR-G5EC8HGKHQ-7	GTFUJIR3	Skin	Skin Cutaneous Melanoma	VARS	SNV	p.T1062M	7	EVADEAMGAL	EVADEATGAL	10					HLA-A25:01	CD8	multimer	patient_TIL	"tumor_cells, peptide_pulsed_APC"	none	0.174	0.08	0.293	0.26052454	0.73		-0.393904286	no	0			PMID:32753545	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
NDDR-ZZYSGAHKME-W	GTFUJIR3	Skin	Skin Cutaneous Melanoma	MYLK	SNV	p.G691V	7	EVFPEDTVTY	EVFPEDTGTY	10	3	123708766	C	A	HLA-A25:01	CD8	multimer	patient_TIL	"tumor_cells, peptide_pulsed_APC"	none	0.004	0.25	0.015	0.2766524	2.89	0.973908	-0.223143551	no	0	0.6236768736843954		PMID:32753545	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
NDDR-VHY0P4RGXB-T	GTFUJIR3	Skin	Skin Cutaneous Melanoma	RBM12	SNV	p.S424L	1	LPHEAGFCV	SPHEAGFCV	9	20	35654052	G	A	HLA-B51:01	CD8	multimer	patient_TIL	"tumor_cells, peptide_pulsed_APC"	none	0.095	0.03	0.051	0.4229979	-0.154	0.969313	-1.105605324	yes	0	3.649667109365193		PMID:32753545	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
NDDR-9KFN92EGN8-J	GTFUJIR3	Skin	Skin Cutaneous Melanoma	LRP3	SNV	p.T722S	9	LTAARPSQSVL	LTAARPSQTVL	11	19	33207160	C	G	HLA-A25:01	CD8	multimer	patient_TIL	"tumor_cells, peptide_pulsed_APC"	none	9.597	3.5	14.249	0.000551931	1.068	0.964317	-0.016636912	no	0	1.5874537988404145		PMID:32753545	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
NDDR-C892E3W17C-U	YJCPSI7I	Skin	Skin Cutaneous Melanoma	ENTPD4	SNV	p.P85L	7	ATDTNNLNVNY	ATDTNNPNVNY 	11	8	23447838	G	A	HLA-A01:01	CD8	multimer	patient_TIL	"tumor_cells, peptide_pulsed_APC"	none	0.022	0.01	0.21	0.6612412	2.864	0.96242	-0.405465108	no	0	3.1196292036020346		PMID:32753545	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
NDDR-Q8ETT3PMN2-D	YJCPSI7I	Skin	Skin Cutaneous Melanoma	TTC37	SNV	p.A692V	6	YLDGKVVDY	YLDGKAVDY	9	5	95520755	G	A	HLA-A01:01	CD8	multimer	patient_TIL	"tumor_cells, peptide_pulsed_APC"	none	0.031	0.9	0.011	0.6774577	2.426		-0.031748698	no	0	3.00543587954074		PMID:32753545	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
NDDR-8FAN95FX4H-Z	YJCPSI7I	Skin	Skin Cutaneous Melanoma	MAB21L1	SNV	p.V321M	9	LRIRDRYVM	LRIRDRYVV	9	13	35475637	C	T	HLA-B08:01	CD8	multimer	patient_TIL	"tumor_cells, peptide_pulsed_APC"	none	5.02	4	6.534	0.023552766	0.808	0.874276	-0.81772426	yes	0	-4.553066360401127		PMID:32753545	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
NDDR-CFTCW1YZ6Y-F	MP5A4MPY	Skin	Skin Cutaneous Melanoma	RAD51AP1-002	SNV	p.S241F	4	KVKFPVEKK	KVKSPVEKK	9	12	4553097	C	T	HLA-A03:01	CD8	multimer	patient_TIL	"tumor_cells, peptide_pulsed_APC"	none	0.018	0.4	0.014	0.54931486	0.738		0.810930216	no	0			PMID:32753545	Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up
NDDR-J7YKRKVGDN-4	VQQXFXNM	Ovary	Ovarian Cancer	HSDL1	SNV	p.L25V	6	CYMEAVALV	CYMEALALV	9	16	84131249	G	C	HLA-C14:03	CD8	ELISPOT	"patient_TIL, PBMC_pre"	peptide_pulsed_APC	none	1.163	12	0.147	0.042784397	0.54	0.365067	-0.234939568	no	0	1.882956006881632		PMID:24323902	Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer
NDDR-YP77ANFST5-G	ZPRTYQED	Skin	Skin Cutaneous Melanoma	COL181A	SNV	p.S126F	8	VLLGVKLFGV	VLLGVKLSGV	10	21	45468512	C	T	HLA-A02:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	TMC_minigene	none	0.491	0.4	0.11	0.52074325	0.402		-0.154441589	no	1			PMID:27827318	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
NDDR-FKNNSG8XXX-E	U4R2OSJM	Skin	Skin Cutaneous Melanoma	RECQL5	SNV	p.P816L	11	GEEDGAGGHSL	GEEDGAGGHSP	11	17	75628976	G	A	HLA-B44:02	CD8	"ELISPOT, 4-1BB"	patient_TIL	TMC_minigene	none	0.826	6	1.532	0.02044143	0.578	0.094773	-2.035037929	no	0	2.0929851697611346		PMID:27827318	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
NDDR-9EBFKS8BE0-B	U4R2OSJM	Skin	Skin Cutaneous Melanoma	UGGT2	SNV	p.P882L	2	GLLDEDFYA	GPLDEDFYA	9	13	95895294	G	A	HLA-A02:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	TMC_minigene	none	0.13	2	0.04	0.6822859	-0.602	0.680007	-5.303381446	no	0	1.7479234185758776	Other Tumor Driver	PMID:27827318	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
NDDR-KDS5AYDE9G-Y	U4R2OSJM	Skin	Skin Cutaneous Melanoma	FBXO21	SNV	p.S250Y	2	SYMIMEIEL	SSMIMEIEL	9	12	117174332	G	T	HLA-C14:02	CD8	"ELISPOT, 4-1BB"	patient_TIL	TMC_minigene	none	0.094	25	0.009	0.7339669	1.302	0.654397	-4.319755046	yes	0	2.5870995364740947		PMID:27827318	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
NDDR-W8302P07KB-T	U4R2OSJM	Skin	Skin Cutaneous Melanoma	XPNPEP1	SNV	p.S639T	10	WLIRETQPITK	WLIRETQPISK	11	10	109865198	A	T	HLA-A03:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	TMC_minigene	none	1.963	2.5	3.516	0.14389448	0.448	0.973393	0.014366589	no	0	3.383917756138871		PMID:27827318	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
NDDR-8HGA5WFX6S-9	PPKWDFGG	Skin	Skin Cutaneous Melanoma	TFDP2	SNV	p.A270T	5	GQFLTPNSH	GQFLAPNSH	9	3	141952638	C	T	HLA-B15:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	TMC_minigene	none	0.369	4	0.388	0.44904605	-0.202	0.806689	-0.057910916	no	0	1.7325407960953627		PMID:27827318	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
NDDR-00P571BG65-G	UCE5HKKE	Skin	Skin Cutaneous Melanoma	PHKA1	SNV	p.P34L	10	HQNPVTGLLL	HQNPVTGLLP	10	X	72712915	G	A	HLA-B38:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	TMC_minigene	none	0.451	0.3	0.227	0.6704648	0.89	0.034755	-2.919148102	no	0	-0.009890635455803		PMID:27827318	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
NDDR-M571B9D7AN-4	UCE5HKKE	Skin	Skin Cutaneous Melanoma	KIAA1967	SNV	p.H227Y	10	RHDLPPYRVYL	RHDLPPYRVHL	11	8	22613111	C	T	HLA-B38:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	TMC_minigene	none	0.125	6	0.595	0.0226748	0.776		-0.031498667	no	0			PMID:27827318	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
NDDR-GBFX050B7K-1	UCE5HKKE	Skin	Skin Cutaneous Melanoma	KIAA1279	SNV	p.P246S	3	YHSIEWAI	YHPIEWAI	8	10	69005862	C	T	HLA-B38:01	CD8	"ELISPOT, 4-1BB"	patient_TIL	TMC_minigene	none	0.184	0.5	0.142	0.4799058	0.332		-0.240385358	no	0			PMID:27827318	Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
NDDR-7052R2DHND-V	OP4YBPHD	Ovary	Ovarian Cancer	BRAP	SNV	p.R543C	3	QLCDVMFYL	QLRDVMFYL	9	12	111644378	G	A	HLA-A02:01	CD8	"ELISPOT, 4-1BB, multimer"	"TCR_clone, healthy_donor_PBMC"	peptide_pulsed_APC	none	0.12	0.4	0.004	0.5973775	0.832	0.972631	-0.416514944	no	0	2.579687030220663		PMID:29720506	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer
NDDR-5S6XME4F5F-X	BCIKPFC2	Ovary	Ovarian Cancer	RFC5	SNV	p.K160N	4	YLSNIIPAL	YLSKIIPAL	9	12	118024909	G	C	HLA-A02:01	CD8	"ELISPOT, 4-1BB, multimer"	"TCR_clone, healthy_donor_PBMC"	peptide_pulsed_APC	none	0.008	0.03	0.005	0.6683105	0.8	0.966923	0	no	0	2.8318772411916733		PMID:29720506	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer
NDDR-3ZY9QZNQXN-4	BCIKPFC2	Ovary	Ovarian Cancer	GINS1	SNV	p.I87V	9	YLYDRLLRV	YLYDRLLRI	9	20	25418124	A	G	HLA-A02:01	CD8	"ELISPOT, 4-1BB, multimer"	"TCR_clone, healthy_donor_PBMC"	peptide_pulsed_APC	none	0.002	0.02	0.007	0.7756753	0.542	0.953791	-1.386294361	no	0	2.389126226924704		PMID:29720506	Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer
NDDR-FZTSJMS64Q-7	FDCHYTN3	Bone marrow	Multiple Myeloma	EVI2B	SNV	p.G327A	9	DSADGSTVATA	DSADGSTVGTA	11	17	31304630	C	G	HLA-A68:02	CD8	ICS	PBMC_pre	peptide_pulsed_APC	none	1.352	10	1.397	0.4630514	-0.736	0.548426	-0.861565832	no	0			PMID:31857430	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
NDDR-91HRG4BTBH-Z	JAR22V53	Bone marrow	Multiple Myeloma	PRKDC	SNV	p.Q823E	9	VSALSRAAEK	VSALSRAAQK	10	8	47918336	G	C	HLA-A03:01	CD8	ICS	PBMC_pre	peptide_pulsed_APC	none	1.679	1.2	3.312	0.14334771	0.636	0.345868	0.412937867	no	0			PMID:31857430	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
NDDR-QCH9V1GARW-D	3PCSYXUC	Bone marrow	Multiple Myeloma	S100A9	SNV	p.T18N	7	IETIINNFHQY	IETIINTFHQY	11	1	153358336	C	A	HLA-B44:03	CD8	ICS	PBMC_pre	peptide_pulsed_APC	none	0.353	0.09	0.822	0.5827813	2.842	0.978122	0.213978877	yes	0			PMID:31857430	Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma
NDDR-AZ9A9GK0V8-J	V4S75ZZC	Lung	Non-Small Cell Lung Cancer (NSCLC)	PGAP1	SNV	p.Y903F	8	AFGSAHLFR	AFGSAHLYR	9	2	196841295	T	A	HLA-A31:01	CD8	"ELISPOT, ICS"	PBMC_pre	peptide_pulsed_APC	endogenous(HLA-block)	0.247	3.5	0.164	0.033942964	1.532	0.213232	0.236388778	no	0	0.6982183795788264		PMID:28031159	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-small Cell Lung Cancer
NDDR-SQGGCG6BKT-A	V4S75ZZC	Lung	Non-Small Cell Lung Cancer (NSCLC)	HELB	SNV	p.P987S	6	SASPLSVV	SASPLPVV	8	12	66331442	C	T	HLA-C15:02	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, patient_TIL"	peptide_pulsed_APC	TMC	1.053	1.6	6.152	0.007815836	0.44	0.206922	0.586078723	no	0	-0.76 		PMID:28031159	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-small Cell Lung Cancer
NDDR-3WA072BDQH-Z	V4S75ZZC	Lung	Non-Small Cell Lung Cancer (NSCLC)	PGAP1	SNV	p.Y903F	10	VIAFGSAHLFR	VIAFGSAHLYR	11	2	196841295	T	A	HLA-A31:01	CD8	"ELISPOT, ICS"	PBMC_pre	peptide_pulsed_APC	endogenous(HLA-block)	0.998	1	0.692	0.017975297	1.686	0.213232	0.245178126	no	0	0.6982183795788264		PMID:28031159	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-small Cell Lung Cancer
NDDR-RJJJVF07Q8-J	V4S75ZZC	Lung	Non-Small Cell Lung Cancer (NSCLC)	SLC26A7	SNV	p.R117Q	8	ISANAVEQIV	ISANAVERIV	10	8	91295576	G	A	HLA-C15:02	CD8	"ELISPOT, ICS"	PBMC_pre	peptide_pulsed_APC	endogenous(HLA-block)	4.912	2.5	1.839	0.11867749	0.41	0.084058	0.125651862	no	0	-4.40 		PMID:28031159	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
NDDR-HRWDRJBJW0-B	V4S75ZZC	Lung	Non-Small Cell Lung Cancer (NSCLC)	HELB	SNV	p.P987S	9	STPSASPLSV	STPSASPLPV	10	12	66331442	C	T	HLA-C15:02	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, patient_TIL"	peptide_pulsed_APC	TMC	1.249	19	8.457	0.013158833	0.376	0.916327	-1.072931732	no	0	-0.76 		PMID:28031159	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
NDDR-VNE4XNP8NJ-0	DXUG6JS4	Skin	Skin Cutaneous Melanoma	MED15	SNV	p.P747S	4	DANSFLQSV	DANPFLQSV	9	22	20586576	C	T	HLA-B51:01	CD8	"multimer, ELISPOT"	patient_TIL	"tumor_cells, peptide_pulsed_APC"	MS	0.01	4	0.001	0.8711061	-0.126	0.965305	0.510825624	yes	0	4.421583505080367		PMID:30209080	Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
NDDR-VFJ1HW8KKQ-7	DXUG6JS4	Skin	Skin Cutaneous Melanoma	NCAPH2	SNV	p.S181Y	3	GVYPMPGTQK	GVSPMPGTQK	10					HLA-A03:01	CD8	"multimer, ELISPOT"	patient_TIL	"tumor_cells, peptide_pulsed_APC"	MS	0.005	0.15	0.016	0.6496652	0.854	0.94295	-2.00148	no	0	4.046185207556744		PMID:30209080	Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma
NDDR-8546NTA30S-9	VXLPQZMT	Colon/Rectum	Colorectal Adenocarcinoma	MYO5B	SNV	p.K1410Q	7	NENLDLQEL	NENLDLKEL	9	18	49849654	T	G	HLA-B40:01	CD8	multimer	PBMC_pre	peptide_pulsed_APC	none	0.128	0.8	0.074	0.08536049	1.02	0.761647	-0.410659925	no	0	3.432878849521966		PMID:38039963	Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
NDDR-4X6MSRCG9M-3	VXLPQZMT	Colon/Rectum	Colorectal Adenocarcinoma	ARMC9	SNV	p.L146F	4	TEFFPFYAL	TEFLPFYAL	9	2	231216725	C	T	HLA-B40:01	CD8	multimer	PBMC_pre	peptide_pulsed_APC	none	0.053	0.5	0.004	0.74692786	1.17	0.975608	0.232622295	no	0	0.19874557636851695		PMID:38039963	Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers
NDDR-ZEXNA40QMF-X	A4433WE5	Skin	Skin Cutaneous Melanoma	SEC22C	SNV	p.H248Y	9	AEHSLQVAY	AEHSLQVAH	9	3	42555989	G	A	HLA-B44:03	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	TMC_minigene	endogenous(HLA-block)	0.003	0.03	0.035	0.65933895	3.264	0.069098	-4.857225081	yes	0	2.964352206962708		PMID:27312342	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
NDDR-BJNX57J42T-A	A4433WE5	Skin	Skin Cutaneous Melanoma	AFMID	SNV	p.A87V	2	EVLPFFLFF	EALPFFLFF	9	17	78202703	C	T	HLA-A29:02	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	TMC_minigene	endogenous(HLA-block)	0.572	1.3	0.006	0.6574246	2.312	0.911089	-0.643876132	yes	0	2.3634910769146917		PMID:27312342	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
NDDR-XRFB4NYHXS-9	A4433WE5	Skin	Skin Cutaneous Melanoma	PRDX3	SNV	p.P44L	4	FFYLLDFTF	FFYPLDFTF	9	10	119174460	G	A	HLA-A29:02	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	TMC_minigene	endogenous(HLA-block)	0.443	1.8	0.157	0.87589324	2.764	0.931843	2.355900152	yes	0	4.902441249653209		PMID:27312342	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
NDDR-Y2Z4X3P1JM-3	A4433WE5	Skin	Skin Cutaneous Melanoma	GCN1	SNV	p.P769L	5	IMQTLAGELY	IMQTPAGELY	10	12	120161916	G	A	HLA-A29:02	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	TMC_minigene	endogenous(HLA-block)	0.447	0.9	0.765	0.95175177	2.946	0.93323	0.794290897	yes	0	4.221440070993674		PMID:27312342	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
NDDR-6CX6JH2JPN-4	A4433WE5	Skin	Skin Cutaneous Melanoma	HELZ2	SNV	p.D45N	3	QTNPVTLQY	QTDPVTLQY	9	20	62198871	G	A	HLA-A29:02	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	TMC_minigene	endogenous(HLA-block)	0.002	0.04	0.015	0.96728057	2.622	0.978844	-1.504077397	yes	0	2.540976820076291		PMID:27312342	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
NDDR-RVJSEHY3SB-T	A4433WE5	Skin	Skin Cutaneous Melanoma	PLSCR4	SNV	p.R247C	3	RVCGPCSTY	RVRGPCSTY	9	3	146196679	G	A	HLA-A29:02	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	TMC_minigene	endogenous(HLA-block)	0.351	1.5	0.748	0.925121	3.282	0.978774	-0.331576266	yes	0	1.5328401626458188		PMID:27312342	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
NDDR-JAZ60H7WTC-U	A4433WE5	Skin	Skin Cutaneous Melanoma	TPX2	SNV	p.H458Y	9	TEDEHFEFY	TEDEHFEFH	9	20	31783880	C	T	HLA-B44:03	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	TMC_minigene	endogenous(HLA-block)	0.062	0.5	0.002	0.7403499	2.564	0.210275	-2.697239285	yes	0	4.681660661213192		PMID:27312342	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
NDDR-RT21NV6BXT-A	A4433WE5	Skin	Skin Cutaneous Melanoma	SRPX	SNV	p.P55L	2	TLWCSPIKV	TPWCSPIKV	9	X	38174345	G	A	HLA-A02:01	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	TMC_minigene	endogenous(HLA-block)	0.082	1.6	0.068	0.5705981	0.636	0.964149	-5.024762673	no	1	5.953749044438666		PMID:27312342	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
NDDR-FZSSX30FWZ-G	A4433WE5	Skin	Skin Cutaneous Melanoma	CENPL	SNV	p.P79L	7	TLYSLTLLY	TLYSLTPLY	9	1	173807451	G	A	HLA-A29:02	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	TMC_minigene	endogenous(HLA-block)	0.001	0.01	0.001	0.9842509	3.276	0.971861	-1.386294361	yes	0	1.234530764796478		PMID:27312342	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
NDDR-S5M12PJKER-8	A4433WE5	Skin	Skin Cutaneous Melanoma	WDR46	SNV	p.T300I	3	FLIYLDVSV	FLTYLDVSV	9	6	33287207	G	A	HLA-A02:01	CD8	"ELISPOT, 4-1BB"	"patient_TIL, TCR_clone"	TMC_minigene	endogenous(HLA-block)	0.123	0.17	0.124	0.5000206	0.2	0.152263	-0.198450939	no	1	5.306262756328292		PMID:27312342	Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens
NDDR-R36XZ74D2F-X	JJRPX753	Breast	Breast Cancer	ROBO3	SNV	p.A1287V	2	RVAGSMSSL	RAAGSMSSL	9	11	124879850	C	T	HLA-B07:02	CD8	ELISPOT	PBMC_pre	"tumor_cells, peptide_pulsed_APC"	endogenous(HLA-block)	0.26	0.6	0.117	0.07093977	1.328	0.967618	0.122602322	no	1	-1.2438306819752205		PMID:28619968	Breast Cancer Neoantigens Can Induce CD8+T-Cell Responses and Antitumor Immunity
NDDR-AHM88B8PVS-9	JJRPX753	Breast	Breast Cancer	PALB2	SNV	p.H198D	9	SPVTEIRTDL	SPVTEIRTHL	10	16	23635954	G	C	HLA-B07:02	CD8	ELISPOT	PBMC_pre	"tumor_cells, peptide_pulsed_APC"	endogenous(HLA-block)	0.154	0.9	0.354	0.13529685	0.594	0.972951	0.746493161	no	1	2.045914337083082	Other Tumor Driver	PMID:28619968	Breast Cancer Neoantigens Can Induce CD8+T-Cell Responses and Antitumor Immunity
NDDR-3ZZYVXS3EE-W	QFNXKYKQ	Breast	Breast Cancer	PTPRS	SNV	p.R1207W	7	RQLEVPWPYI	RQLEVPRPYI	10	19	5220088	G	A	HLA-A02:01	CD8	ELISPOT	PBMC_pre	"tumor_cells, peptide_pulsed_APC"	none	0.592	1.6	0.582	0.08275931	1.004	0.560228	-0.340325806	no	1	2.6617720334514887		PMID:28619968	Breast Cancer Neoantigens Can Induce CD8+T-Cell Responses and Antitumor Immunity
NDDR-407E004WJN-4	PE5QXW4K	Breast	Breast Cancer	ZDHHC16	SNV	p.H288L	9	ALGALTVWL	ALGALTVWH	9	10	97455698	A	T	HLA-A02:01	CD8	ELISPOT	PBMC_pre	"tumor_cells, peptide_pulsed_APC"	none	0.574	3.5	0.206	0.55235475	0.894	0.038458	-3.570758818	no	1	3.8864525971067927		PMID:28619968	Breast Cancer Neoantigens Can Induce CD8+T-Cell Responses and Antitumor Immunity
NDDR-KQ8T2M2TH4-F	6VPEE6FY	Colon/Rectum	Colorectal Adenocarcinoma	TP53	SNV	p.Y220C	4	VVPCEPPEV	VVPYEPPEV	9					HLA-A02:01	CD8	"ELISPOT, 4-1BB, HLA-block"	patient_TIL	peptide_pulsed_APC	endogenous(HLA-block)	0.751	9	1.073	0.3173151	0.454	0.687508	0.629941105	no	1	4.49708538278116	Tumor Driver	PMID:30714987	Neoantigen screening identifies broadTP53mutant immunogenicity in patients with epithelial cancers
NDDR-2RKK51DFKZ-G	TE6XNJKV	Colon/Rectum	Colorectal Adenocarcinoma	TP53	SNV	p.R175H	8	HMTEWRHC	HMTEWRHR	8					HLA-A02:01	CD8	"ELISPOT, 4-1BB, HLA-block"	patient_TIL	peptide_pulsed_APC	endogenous(HLA-block)	30.273	6	38.64	0.29153964	-0.036		-0.287954555	no	0	4.49708538278116	Tumor Driver	PMID:30714987	Neoantigen screening identifies broadTP53mutant immunogenicity in patients with epithelial cancers
NDDR-Y5YMFQGM88-J	RXNERV56	Colon/Rectum	Colorectal Adenocarcinoma	TP53	SNV	p.R175H	8	HMTEWRHC	HMTEWRHR	8					HLA-A02:01	CD8	"ELISPOT, 4-1BB, HLA-block"	patient_TIL	peptide_pulsed_APC	endogenous(HLA-block)	30.273	6	38.64	0.29153964	-0.036		-0.287954555	no	0	4.49708538278116	Tumor Driver	PMID:30714987	Neoantigen screening identifies broadTP53mutant immunogenicity in patients with epithelial cancers
NDDR-XZCQ5QV77G-Y	I4ZR7YUA	Colon/Rectum	Colorectal Adenocarcinoma	TP53	SNV	p.R248W	9	SSCMGGMNWR	SSCMGGMNRR	10	17	7674221	G	A	HLA-A68:01	CD8	"ELISPOT, 4-1BB, HLA-block"	patient_TIL	peptide_pulsed_APC	endogenous(HLA-block)	0.995	1.6	1.964	0.19980375	1.654	0.066026	0.526015789	no	0	4.49708538278116	Tumor Driver	PMID:30714987	Neoantigen screening identifies broadTP53mutant immunogenicity in patients with epithelial cancers
NDDR-YVEY0T9SF2-D	JXPQ4HGM	Stomach	Gastric Adenocarcinoma	OR10H1	SNV	p.E297V	2	KVLKVAMKK	KELKVAMKK	9					HLA-A03:01	CD8	4-1BB	PBMC_postVax	peptide_pulsed_APC	endogenous(HLA-block)	0.007	0.02	0.013	0.592961	0.778	0.92175	-5.894009211	no	0	-6.1177873781071375		PMID:33016924	mRNA vaccine induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
NDDR-0NVE3V4N95-G	JXPQ4HGM	Stomach	Gastric Adenocarcinoma	COL6A3	SNV	p.G346W	3	TAWQSEDSY	TAGQSEDSY	9					HLA-B35:01	CD8	4-1BB	PBMC_postVax	peptide_pulsed_APC	endogenous(HLA-block)	0.04	2	0.082	0.21853267	3.314	0.428246	-1.977547234	yes	0	5.05876781757472	Other Tumor Driver	PMID:33016924	mRNA vaccine induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer
NDDR-RP96B6V4BF-X	ONOD4DCC	Skin	Skin Cutaneous Melanoma	ERBB2	SNV	p.H197Y	8	ALIHHNTYL	ALIHHNTHL	9	17	39715843	C	T	HLA-A02:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.058	0.2	0.007	0.6004392	1.358	0.958901	-0.759838555	no	1	2.7079102909912973	Other Tumor Driver	PMID:26389673	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
NDDR-QSCW08XXWJ-0	ONOD4DCC	Skin	Skin Cutaneous Melanoma	COL18A1	SNV	p.S306F	7	LLGVKLFGV	LLGVKLSGV	9					HLA-A02:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.452	0.8	0.339	0.39031768	0.042	0.915367	-0.475244298	no	0	4.191604908313973		PMID:26389673	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
NDDR-3WX67JTZB5-G	ONOD4DCC	Skin	Skin Cutaneous Melanoma	TEAD1	SNV	p.L209F	9	SVLENFTIFL	SVLENFTILL	10	11	12930323	A	T	HLA-A02:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	1.119	1.9	0.083	0.22353907	1.174	0.967589	-0.077358142	no	1	3.555239427242588		PMID:26389673	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
NDDR-3FZN4MKTRM-3	ONOD4DCC	Skin	Skin Cutaneous Melanoma	TEAD1	SNV	p.L209F	8	VLENFTIFLV	VLENFTILLV	10	11	12930323	A	T	HLA-A02:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	2.259	0.7	0.1	0.5003603	0.078	0.884139	-0.022758094	no	1	3.555239427242588		PMID:26389673	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
NDDR-3XTZVS0C4T-A	5K3HKC6D	Skin	Skin Cutaneous Melanoma	NSDHL	SNV	p.A290V	9	ILTGLNYEV	ILTGLNYEA	9	X	152868863	C	T	HLA-A02:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.067	0.17	0.028	0.57955974	0.218	0.562207	-2.354922618	no	1	3.800138646972027		PMID:26389673	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
NDDR-6JWME6V17H-Z	Y3BFVLAR	Skin	Skin Cutaneous Melanoma	GANAB	SNV	p.S184F	5	ALYGFVPVL	ALYGSVPVL	9	11	62632668	G	A	HLA-A02:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.022	0.4	0.007	0.6907953	1.594	0.973129	-0.167054085	no	1	6.979636638529511		PMID:26389673	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
NDDR-PKEAHAWX4S-9	J6KE3KIV	Skin	Skin Cutaneous Melanoma	TRIP12	SNV	p.F1544S	2	PSDTRQMLFY	PFDTRQMLFY	10	2	229787644	A	G	HLA-A01:01	CD8	multimer	patient_TIL	peptide_pulsed_APC	none	0.036	0.09	0.022	0.39014745	2.326	0.544087	-3.218875825	no	1	3.995384355392576		PMID:26389673	Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
NDDR-CZRBXE09Z4-F	HVWWYCPV	Stomach	Gastric Cancer	CYP2A6	SNV	p.N438Y	3	KRYCFGEGL	KRNCFGEGL	9					HLA-B14:02	CD8	ELISPOT	PBMC_pre	"peptide_pulsed_APC, TMC_minigene"	none	1.536	0.15	0.296	0.19199942	1.8	0.56948	-0.78721369	no	0	-3.5454031892926263	Other Tumor Driver	PMID:30835255	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
NDDR-NYC0KZGC6A-S	HVWWYCPV	Stomach	Gastric Cancer	CYP2A6	SNV	p.N438Y	3	KRYCFGEGL	KRNCFGEGL	9					HLA-C07:04	CD8	ELISPOT	PBMC_pre	"peptide_pulsed_APC, TMC_minigene"	none	2.72	18	7.923	0.05841868	1.8	0.56948	0.126413925	no	0	-3.5454031892926263	Other Tumor Driver	PMID:30835255	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
NDDR-4FDB71EDHG-Y	M4XLJUGS	Uterus	Endometrial Cancer	KRAS	SNV	p.G12C	5	VVGACGVGK	VVGAGGVGK	9					HLA-A11:01	CD8	ELISPOT	PBMC_pre	"peptide_pulsed_APC, TMC_minigene"	none	0.676	0.6	0.284	0.10408942	0.308	0.49574	1.15490091	no	1	2.6672328924875006	Tumor Driver	PMID:30835255	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
NDDR-0FHEYJAFS7-I	DZZUH7EK	Pancreas	Pancreatic Adenocarcinoma (PDAC)	TP53	SNV	p.V25G	2	RGRAMAIYK	RVRAMAIYK	9					HLA-A30:01	CD8	ELISPOT	PBMC_pre	"peptide_pulsed_APC, TMC_minigene"	none	0.021	0.03	0.024	0.2952876	0.574	0.656203	1.945910149	no	0	3.101902155953119	Tumor Driver	PMID:30835255	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
NDDR-AT9B4Z8C95-G	SFB6K5FA	Pancreas	Pancreatic Adenocarcinoma (PDAC)	KRAS	SNV	p.G12V	8	KLVVVGAVGV	KLVVVGAGGV	10	1	114716126	C	A	HLA-A02:01	CD8	ELISPOT	PBMC_pre	"peptide_pulsed_APC, TMC_minigene"	none	2.879	1.3	1.036	0.51598555	0.63	0.35561	-0.74854804	no	1	3.0308304301532742	Tumor Driver	PMID:30835255	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
NDDR-4TAAMCST6Y-F	SYIVONAA	Thymus	Thymoma	CDC73	SNV	p.Q254E	7	NIFAILESV	NIFAILQSV	9					HLA-A02:01	CD8	ELISPOT	PBMC_pre	"peptide_pulsed_APC, TMC_minigene"	none	0.247	0.9	0.077	0.41550258	0.894	0.963731	0.427983972	no	0	2.065791145294461	Other Tumor Driver	PMID:30835255	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
NDDR-N6HR7DRVC2-D	EZJCG5SK	Lung	Lung Cancer	KRAS	SNV	p.G12A	5	VVGAAGVGK	VVGAGGVGK	9					HLA-A11:01	CD8	ELISPOT	PBMC_pre	"peptide_pulsed_APC, TMC_minigene"	none	0.206	0.6	0.219	0.08056308	0.308	0.49574	-0.033415997	no	1	3.247616066270549	Other Tumor Driver	PMID:30835255	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
NDDR-3G50Q8D15Z-G	D4OVDCY4	Pancreas	Pancreatic Adenocarcinoma (PDAC)	KRAS	SNV	p.G12D	5	VVGADGVGK	VVGAGGVGK	9					HLA-A11:01	CD8	ELISPOT	PBMC_pre	"peptide_pulsed_APC, TMC_minigene"	none	0.452	1.2	0.229	0.05571235	0.308	0.49574	0.752390014	no	1	3.0308304301532742	Tumor Driver	PMID:30835255	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
NDDR-P9VVWP3AAQ-7	47LXN6PR	Pancreas	Pancreatic Adenocarcinoma (PDAC)	KRAS	SNV	p.G12V	5	VVGAVGVGK	VVGAGGVGK	9					HLA-A11:01	CD8	ELISPOT	PBMC_pre	"peptide_pulsed_APC, TMC_minigene"	none	0.128	0.5	0.076	0.22968939	0.308	0.49574	-0.509261902	no	1	3.0308304301532742	Tumor Driver	PMID:30835255	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
NDDR-8WT94E5KH5-G	GXEZJAFU	Pancreas	Pancreatic Adenocarcinoma (PDAC)	KRAS	SNV	p.G12D	8	KLVVVGADGV	KLVVVGAGGV	10	12	25245350	C	T	HLA-A02:01	CD8	ELISPOT	PBMC_pre	"peptide_pulsed_APC, TMC_minigene"	none	5.155	2.5	2.765	0.30073658	0.63	0.35561	-0.166023934	no	1	3.0308304301532742	Tumor Driver	PMID:30835255	Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
NDDR-76CBJC44KN-4	AMBE3DOP	Blood/Bone marrow	Chronic Lymphocytic Leukemia	C6ORF89	SNV	p.Y318C	10	MPIEPGDIGC	MPIEPGDIGY	10					HLA-B35:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	1.739	0.9	0.783	0.65973526	-0.4	0.845155	4.822008185	yes	1	3.5961957207627404		PMID:24891321	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
NDDR-C06RNEZ45R-8	AMBE3DOP	Blood/Bone marrow	Chronic Lymphocytic Leukemia	ALMS1	SNV	p.G1001S	7	TPTVPSSSF	TPTVPSGSF	9	2	73449528	G	A	HLA-B35:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.032	0.7	0.039	0.14113191	1.858	0.977371	-1.188224447	yes	1	2.501133376060947	Other Tumor Driver	PMID:24891321	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
NDDR-5S8F797ZQ0-B	V4UEFDFP	Blood/Bone marrow	Chronic Lymphocytic Leukemia	FNDC3B	SNV	p.L294M	3	VVMSWAPPV	VVLSWAPPV	9	3	172295393	T	A	HLA-A02:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.435	0.05	1.3	0.37867132	0.614	0.947741	-0.359200488	no	1	4.124237136458928	Other Tumor Driver	PMID:24891321	Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
NDDR-R061VV3SA3-E	7KQJQFYF	Colon/Rectum	Colorectal Adenocarcinoma	AKT1	SNV	p.E17K	1	KYIKTWRPRYF	EYIKTWRPRYF	11	14	104780214	C	T	HLA-A23:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	"tumor_cells, peptide_pulsed_APC"	endogenous(HLA-block)	0.134	0.08	0.731	0.21049616	2.984	0.606498	-0.578623752	no	1	3.481712259170993	Tumor Driver	PMID:30841906	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
NDDR-0ADS7G1KFJ-0	IKJKM6CH	Lung	Non-Small Cell Lung Cancer (NSCLC)	BRAF	SNV	p.N581I	2	NIIFLHEDLTV	NNIFLHEDLTV	11	7	140753393	T	A	HLA-A02:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	"tumor_cells, peptide_pulsed_APC"	endogenous(HLA-block)	5.797	5.5	1.733	0.19390954	0.808	0.804862	-1.275639345	no	0	0.5641331742871212	Tumor Driver	PMID:30841906	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
NDDR-NADW9979N0-B	YE643ISX	Ovary	Ovarian Cancer (epithelial)	IL27RA	SNV	p.P594L	6	EEMEPLPVM	EEMEPPPVM	9	19	14052160	C	T	HLA-B44:03	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.048	1.2	0.079	0.18478033	0.072	0.972839	0.344840486	yes	0	2.190393619472398		PMID:31221207	Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
NDDR-2D8VM6B57P-6	7U4C6SW6	Ovary	Ovarian Cancer (epithelial)	CCR6	SNV	p.V67L	4	FGLLGNILLVI	FGLVGNILLVI	11	6	167136429	G	C	HLA-A02:24	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	3.985	13	6.659	0.44010946	0.108		-0.667346677	no	0	-7.828280760912152		PMID:31221207	Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
NDDR-1PA1KV8VFV-C	7U4C6SW6	Ovary	Ovarian Cancer (epithelial)	FCGBP	SNV	p.A1177V	2	FVLSGESCLPL	FALSGESCLPL	11					HLA-A02:06	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	2.749	0.8	2.226	0.11389381	0.856	0.935466	-1.108986326	no	0	1.3802861561230784		PMID:31221207	Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
NDDR-25ES7DSS0P-6	7U4C6SW6	Ovary	Ovarian Cancer (epithelial)	TRPC4	SNV	p.G577V	9	QSLFWSIFV	QSLFWSIFG	9	13	37655242	C	A	HLA-A69:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	"peptide_pulsed_APC, tumor_cells"	endogenous(HLA-block)	0.432	2.5	0.095	0.18444404	0.296	0.026861	-4.502891337	yes	0	-4.636660688370521		PMID:31221207	Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer
NDDR-YE0KNS4DEP-6	U2DXRUJY	Skin	Skin Cutaneous Melanoma	ATR	SNV	p.S296L	8	KLYEEPLLK	KLYEEPLSK	9	3	142562515	G	A	HLA-A03:01	CD8	"ELISPOT, ICS, multimer"	"patient_TIL, PBMC_pre, PBMC_postVax"	"peptide_pulsed_APC, tumor_cells"	"endogenous(HLA-block), TMC"	0.001	0.01	0.001	0.5631237	0.998	0.932912	0	no	1	0.2944289114832716	Tumor Driver	PMID:24043743	Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive Melanoma
NDDR-MK3JG6S0PH-Z	OZBCLZO4	Lung	Non-Small Cell Lung Cancer (NSCLC)	EGFR	SNV	p.T790M	3	LIMQLMPFGCL	LITQLMPFGCL	11	7	55181378	C	T	HLA-A02:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, patient_Tc_line, healthy_donor_PBMC"	peptide_pulsed_APC	endogenous(HLA-block)	10.886	3.5	5.825	0.14237472	1.254	0.366241	-0.669490913	no	1	3.9243374515578378	Tumor Driver	PMID:24223798	EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation
NDDR-AKP23P0HMV-C	OZBCLZO4	Lung	Non-Small Cell Lung Cancer (NSCLC)	EGFR	SNV	p.T790M	1	MQLMPFGCLL	TQLMPFGCLL	10	7	55181378	C	T	HLA-A02:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, patient_Tc_line, healthy_donor_PBMC"	peptide_pulsed_APC	endogenous(HLA-block)	2.973	6.5	4.315	0.24933057	1.232	0.957875	-0.02294365	no	1	3.9243374515578378	Tumor Driver	PMID:24223798	EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation
NDDR-QS7NRQ41FQ-7	XYLTPHZM	Skin	Skin Cutaneous Melanoma	MMS22L	SNV	p.S437F	10	EYYSKNLNSF	EYYSKNLNSS	10	6	97231645	G	A	HLA-A24:02	CD8	"ELISPOT, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells, cDNA_cell_line"	endogenous(HLA-block)	0.068	0.8	0.482	0.38734272	2.684	0.0462	-5.107192468	no	0	-0.7602358908480553		PMID:28423700	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model
NDDR-NX70ZZP0CP-6	MILOVCNS	Skin	Skin Cutaneous Melanoma	HERPUD1	SNV	p.G161S	8	GLGPGFSSY	GLGPGFSGY	9	16	56939286	G	A	HLA-B15:01	CD8	"ELISPOT, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells, cDNA_cell_line"	endogenous(HLA-block)	0.022	0.4	0.021	0.09945778	2.496	0.963264	-1.984131362	no	0	4.4519363984538245		PMID:28423700	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model
NDDR-HG03BBJD3N-4	4RMAUA5K	Skin	Skin Cutaneous Melanoma	PRDM10	SNV	p.S1050F	9	TYLPSAWNF	TYLPSAWNS	9	11	129910529	G	A	HLA-A24:02	CD8	"ELISPOT, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells, cDNA_cell_line"	endogenous(HLA-block)	0.002	0.01	0.014	0.62892807	2.7	0.064137	-7.095478885	no	0	0.6235832374351025		PMID:28423700	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model
NDDR-T0Z17A2M22-D	RUNCUPXH	Skin	Skin Cutaneous Melanoma	PRDM10	SNV	p.S1050F	9	TYLPSAWNFF	TYLPSAWNSF	10	11	129910529	G	A	HLA-A24:02	CD8	"ELISPOT, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells, cDNA_cell_line"	endogenous(HLA-block)	0.009	0.03	0.038	0.47059944	2.7	0.957051	0.251314428	no	0	0.6235832374351025		PMID:28423700	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model
NDDR-AHDSK0DNZH-Z	ATSSHWMT	Skin	Skin Cutaneous Melanoma	INSIG1	SNV	p.S238F	6	VYQYTFPDF	VYQYTSPDF	9	7	155302755	C	T	HLA-A24:02	CD8	"ELISPOT, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells, cDNA_cell_line"	endogenous(HLA-block)	0.021	0.12	0.002	0.4353292	2.674	0.200933	-0.566395475	no	0	3.4989312813161737		PMID:28423700	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model
NDDR-GFP4PGXK3P-6	P3V3F57E	Skin	Skin Cutaneous Melanoma	INSIG1	SNV	p.S238F	6	VYQYTFPDFL	VYQYTSPDFL	10	7	155302755	C	T	HLA-A24:02	CD8	"ELISPOT, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells, cDNA_cell_line"	endogenous(HLA-block)	0.45	0.3	0.078	0.3607351	1.094	0.480538	0.083381609	no	0	3.4989312813161737		PMID:28423700	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model
NDDR-GGGN8GD973-E	SLHIGIK4	Skin	Skin Cutaneous Melanoma	INSIG1	SNV	p.S238F	5	YQYTFPDF	YQYTSPDF	8	7	155302755	C	T	HLA-A24:02	CD8	"ELISPOT, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells, cDNA_cell_line"	endogenous(HLA-block)	2.1	7.5	9.398	0.08030745	2.974	0.200933	-0.44895022	no	0	3.4989312813161737		PMID:28423700	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model
NDDR-0TX1EYJWDC-U	CAQZ3K3K	Skin	Skin Cutaneous Melanoma	INSIG1	SNV	p.S238F	5	YQYTFPDFLY	YQYTSPDFLY	10	7	155302755	C	T	HLA-A24:02	CD8	"ELISPOT, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells, cDNA_cell_line"	endogenous(HLA-block)	1.647	12	1.474	0.012628782	3.364	0.96755	0.392795255	no	0	3.4989312813161737		PMID:28423700	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model
NDDR-0CP0AVXH3A-S	BBZ33E2J	Skin	Skin Cutaneous Melanoma	MMS22L	SNV	p.S437F	8	YSKNLNSFF	YSKNLNSSF	9					HLA-A24:02	CD8	"ELISPOT, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells, cDNA_cell_line"	endogenous(HLA-block)	2.402	3.5	0.93	0.030581463	2.47	0.911966	0.087844363	no	0	-0.7602358908480553		PMID:28423700	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model
NDDR-F4N0FN189Q-7	VX46FFYO	Skin	Skin Cutaneous Melanoma	MMS22L	SNV	p.S437F	9	YYSKNLNSF	YYSKNLNSS	9	6	97231645	G	A	HLA-A24:02	CD8	"ELISPOT, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells, cDNA_cell_line"	endogenous(HLA-block)	0.003	0.06	0.007	0.40572074	2.532	0.0462	-7.35372233	no	0	-0.7602358908480553		PMID:28423700	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model
NDDR-8DJBG1WJ00-B	KX4N5RSA	Skin	Skin Cutaneous Melanoma	MMS22L	SNV	p.S437F	9	YYSKNLNSFF	YYSKNLNSSF	10	6	97231645	G	A	HLA-A24:02	CD8	"ELISPOT, ICS"	PBMC_pre	"peptide_pulsed_APC, tumor_cells, cDNA_cell_line"	endogenous(HLA-block)	0.031	0.04	0.057	0.32852235	2.532	0.911966	-0.121360857	no	0	-0.7602358908480553		PMID:28423700	HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human Melanoma model
NDDR-2XV4D1HBF7-I	NBE6WCJN	Ovary	Ovarian Cancer	DPY19L4	SNV	p.L143F	5	LYPEFIASI	LYPELIASI	9	8	94739496	C	T	HLA-A24:02	CD8	"ELISPOT, ICS"	"healthy_donor_PBMC, PBMC_pre, patient_Tc_line, TCR_clone"	"peptide_pulsed_APC, cDNA_cell_line"	endogenous(HLA-block)	0.05	0.05	0.009	0.31107822	0.71	0.933351	0.105360516	no	0	2.3199358007315727		PMID:29541393	Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells
NDDR-9G5GW03V3V-C	PC7T4K3B	Ovary	Ovarian Cancer	RNF19B	SNV	p.V372L	2	MLIGIPVYV	MVIGIPVYV	9	1	32946434	C	G	HLA-A02:01	CD8	"ELISPOT, ICS"	"healthy_donor_PBMC, PBMC_pre, patient_Tc_line, TCR_clone"	"peptide_pulsed_APC, cDNA_cell_line"	endogenous(HLA-block)	0.015	0.09	0.006	0.7612357	0.482	0.811435	-1.402823663	no	0	4.1546966138277375		PMID:29541393	Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells
NDDR-T8XPXGAW5J-0	ZEWNQSDP	Skin	Skin Cutaneous Melanoma	MED15	SNV	p.P677S	4	DANSFLQSV	DANPFLQSV	9	22	20586576	C	T	HLA-B51:01	CD8	"ELISPOT, ICS"	"PBMC_pre, patient_Tc_line"	"peptide_pulsed_APC, tumor_cells"	"MS, endogenous(HLA-block)"	0.01	4	0.001	0.8711061	-0.126	0.965305	0.510825624	yes	0	4.421583505080367		PMID:26819371	Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens
NDDR-97N3S6RFMR-8	FKQHULMK	Adrenal/Sympathetic nervous system	Neuroblastoma	ALK	SNV	p.R1275Q	2	AQDIYRASY	ARDIYRASY	9	2	29209798	C	T	HLA-B15:01	CD8	multimer	healthy_donor_PBMC	peptide_pulsed_APC	endogenous(HLA-block)	0.116	1.6	0.066	0.7444982	3.05	0.975322	-3.547683294	no	1		Tumor Driver	PMID:29441070	A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations
NDDR-1KM1369VHT-A	FS2BPVBA	Adrenal/Sympathetic nervous system	Neuroblastoma	ALK	SNV	p.R1275Q	2	AQDIYRASYY	ARDIYRASYY	10	2	29209798	C	T	HLA-B15:01	CD8	multimer	healthy_donor_PBMC	peptide_pulsed_APC	endogenous(HLA-block)	0.273	2.5	0.548	0.6774427	3.05	0.755054	-3.326036916	no	1		Tumor Driver	PMID:29441070	A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations
NDDR-EH6J52GFPR-8	BRC35DEQ	Skin	Skin Cutaneous Melanoma	ETV6	SNV	p.L340V	1	VLWDYVYQL	LLWDYVYQL	9	6	36369063	G	C	HLA-A02:01	CD8	HLA-block	patient_TIL	peptide_pulsed_APC	MS	0.004	0.06	0.001	0.8043776	1.35	0.9792	-0.559615788	no	1	2.839596604861465	Other Tumor Driver	PMID:31921104	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
NDDR-T74Q80PSFJ-0	BRC35DEQ	Skin	Skin Cutaneous Melanoma	ETV6	SNV	p.L340V	1	VLWDYVYQLL	LLWDYVYQLL	10	6	36369063	G	C	HLA-A02:01	CD8	"HLA-block, multimer, CD107a"	patient_TIL	peptide_pulsed_APC	none	0.213	0.3	0.125	0.60489655	1.35	0.721166	-0.493779756	no	1	2.839596604861465	Other Tumor Driver	PMID:31921104	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
NDDR-Q7H8S9E5T3-E	7BEVRZEZ	Skin	Skin Cutaneous Melanoma	WDR75	SNV	p.S749F	1	FMFVNSLLL	SMFVNSLLL	9	2	189474766	C	T	HLA-A02:01	CD8	"HLA-block, multimer, CD107a"	patient_TIL	peptide_pulsed_APC	none	0.237	0.6	0.485	0.4168099	1.036	0.973897	-0.843674668	no	1	3.139877612000268		PMID:31921104	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
NDDR-117KNP89MY-F	7BEVRZEZ	Skin	Skin Cutaneous Melanoma	KDELR2	SNV	p.T121I	4	ILWIFSIYL	ILWTFSIYL	9	22	38481222	C	T	HLA-A02:01	CD8	"HLA-block, multimer, CD107a"	patient_TIL	peptide_pulsed_APC	none	0.532	0.4	0.019	0.6383039	1.274	0.978254	1.505958865	no	0	6.081459702108129		PMID:31921104	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
NDDR-KH4CV1H7MW-D	7BEVRZEZ	Skin	Skin Cutaneous Melanoma	MYLIP	SNV	p.P8L	2	RLDAVLMEV	RPDAVLMEV	9	6	16129345	C	T	HLA-A02:01	CD8	"HLA-block, multimer, CD107a"	patient_TIL	peptide_pulsed_APC	none	0.022	0.01	0.007	0.6539008	0.184	0.969844	-5.545709973	no	1	3.914406540292237		PMID:31921104	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
NDDR-MC9PF0RRZ9-K	7BEVRZEZ	Skin	Skin Cutaneous Melanoma	SVIL	SNV	p.E2183K	5	YLTDKDFEFA	YLTDEDFEFA	10	10	29458445	C	T	HLA-A02:01	CD8	"HLA-block, multimer, CD107a"	patient_TIL	peptide_pulsed_APC	none	0.654	1.2	0.314	0.32436848	-0.754	0.077108	-0.223754985	no	1	2.481725171677818		PMID:31921104	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
NDDR-KBBNZ0V0YJ-0	7BEVRZEZ	Skin	Skin Cutaneous Melanoma	CCT4	SNV	p.S115F	1	FLLDSCTKL	SLLDSCTKL	9					HLA-A02:01	CD8	HLA-block	patient_TIL	peptide_pulsed_APC	MS	0.03	0.07	0.034	0.6819849	0.738	0.978012	-1.029619417	no	1	5.646922116939426		PMID:31921104	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
NDDR-HFYS7GCRJP-6	BRC35DEQ	Skin	Skin Cutaneous Melanoma	NUP210	SNV	p.S427F	8	AIDAALTFV	AIDAALTSV	9	3	13376304	G	A	HLA-A02:01	CD8	"HLA-block, multimer, CD107a"	patient_TIL	peptide_pulsed_APC	none	0.33	0.7	0.021	0.5289944	0.344	0.833869	0.681098842	no	1	3.3153894563534725		PMID:31921104	Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display
NDDR-AM42KWVSZE-W	YJOSS4J7	Kidney	Clear Cell Renal Cell Carcinoma	ADARB1	SNV	p.S430F	1	FLLRFLYTQL	SLLRFLYTQL	10	21	45182711	C	T	HLA-A02:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	1.027	0.4	0.193	0.42023903	0.738	0.968085	-0.090251821	no	0	1.883327472971322		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-NHGGDAJ686-H	YJOSS4J7	Kidney	Clear Cell Renal Cell Carcinoma	SLC25A19	SNV	p.G190R	10	TLIAIFPYARL	TLIAIFPYAGL	11	17	75277388	C	T	HLA-A02:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	2.749	2.5	1.817	0.22553797	1.07	0.96574	-0.02336975	no	0	0.6382125876388375		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-BAGKSM08VC-U	YJOSS4J7	Kidney	Clear Cell Renal Cell Carcinoma	PCDH8	SNV	p.R940H	4	SPPHPGRLPDL	SPPRPGRLPDL	11	13	52844663	C	T	HLA-B07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.469	1.5	0.58	0.04200774	0.408	0.964318	-0.079878679	no	0	-9.965784284662089		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-Q973S97QZX-E	YJOSS4J7	Kidney	Clear Cell Renal Cell Carcinoma	PARP4	SNV	p.T1170I	7	KENSLIIQF	KENSLITQF	9	13	24442624	G	A	HLA-B18:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.058	0.25	0.012	0.5344325	2.52	0.45129	-0.066691374	no	0	4.176241693524634	Other Tumor Driver	PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-ANQGPTE9P1-C	YJOSS4J7	Kidney	Clear Cell Renal Cell Carcinoma	RAB39B	SNV	p.W5R	5	MEAIRLYQF	MEAIWLYQF	9	X	155264276	A	T	HLA-B18:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.053	0.03	0.006	0.7067172	2.612	0.741549	-0.140581951	no	0	-1.3580841439264495		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-Z7CCYG5QGE-W	YJOSS4J7	Kidney	Clear Cell Renal Cell Carcinoma	SLC25A19	SNV	p.G190R	2	ARLQFSCYSSL	AGLQFSCYSSL	11	17	75277388	C	T	HLA-C07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	4.939	9.5	4.987	0.22069205	1.568	0.700563	-1.948625344	no	0	0.6382125876388375		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-ZC27261938-J	YJOSS4J7	Kidney	Clear Cell Renal Cell Carcinoma	ZNF567	SNV	p.V575L	9	FRQKTNLIL	FRQKTNLIV	9	19	36720540	G	C	HLA-C07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.074	4.5	0.092	0.7459626	0.95	0.825615	-2.009482953	no	0	0.2979540847343163		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-M9AGD63GT5-G	YJOSS4J7	Kidney	Clear Cell Renal Cell Carcinoma	RAB39B	SNV	p.W5R	2	IRLYQFRLIV	IWLYQFRLIV	10	X	155264276	A	T	HLA-C07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	10.326	28	4.299	0.655081	0.638	0.670805	-1.028311182	no	0	-1.3580841439264495		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-4EJYN1WKM2-D	YJOSS4J7	Kidney	Clear Cell Renal Cell Carcinoma	RAB39B	SNV	p.W5R	2	IRLYQFRLIVI	IWLYQFRLIVI	11	X	155264276	A	T	HLA-C07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	20.391	28	2.646	0.25817725	0.858	0.6358	-0.352202203	no	0	-1.3580841439264495		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-TEFPFSQZHF-X	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	NEK10	SNV	p.D145Y	11	VLICLRLLMRY	VLICLRLLMRD	11	3	27322191	C	A	HLA-B15:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	5.92	1.4	2.951	0.03162649	3.114	0.024991	-2.721473221	no	0	-3.399732054369197		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-FE4XSYS8S3-E	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	CTSF	SNV	p.T246S	3	FRSIYLNTLL	FRTIYLNTLL	10	11	66566152	G	C	HLA-C07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	1.699	7	0.398	0.7893434	1.006	0.849469	-0.199439267	no	0	4.256249630145267		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-EK1K8GPQ5W-D	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	PRKAR2A	SNV	p.L187I	3	LYIWFKTACL	LYLWFKTACL	10					HLA-C07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	4.929	11	5.32	0.61311805	1.298		-0.332027979	no	0	2.854514364166717		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-7GPH5H00GS-9	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	ARHGAP28	SNV	p.K412E	3	MLEYQKILWKV	MLKYQKILWKV	11	18	6890062	A	G	HLA-A02:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	2.986	2	7.585	0.16750674	0.056	0.856781	-0.018580495	no	0	0.3371934800710375		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-NZJXQC4WSN-4	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	PRKAR2A	SNV	p.L187I	6	TQFLYIWFK	TQFLYLWFK	9					HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.354	1.5	0.009	0.5190069	0.878		-0.233261681	no	0	2.854514364166717		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-4WVHS0EVSF-X	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	GDF5	SNV	p.K349R	10	ALFLVFGRTRK	ALFLVFGRTKK	11	20	35434369	T	C	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	1.475	0.7	1.087	0.12049223	0.954	0.803062	0.221450071	no	0	-5.066127282219316		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-N7NFDNFWFW-D	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	ARHGAP28	SNV	p.K412E	8	HIIRLMLEY	HIIRLMLKY	9	18	6890062	A	G	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.9	14	1.554	0.05545967	3.09	0.851749	-0.129077042	no	0	0.3371934800710375		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-6N18E4N5PH-Z	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	C20orf27	SNV	p.C156Y	3	GTYVRVTVQAR	GTCVRVTVQAR	11					HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	2.443	1.2	2.36	0.12911811	1.782		-0.77730622	no	0	3.868597856901992		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-BDK1XB68PD-V	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	ARHGAP28	SNV	p.K412E	4	LMLEYQKILWK	LMLKYQKILWK	11	18	6890062	A	G	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	5.117	3.5	3.175	0.14340997	0.664	0.218072	-0.056419861	no	0	0.3371934800710375		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-8K66P64TP3-E	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	F2RL2	SNV	p.K67T	9	WTGATITVTIK	WTGATITVKIK	11	5	76618507	T	G	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	4.789	2.5	1.401	0.1520231	0.01	0.721694	-0.009973072	no	0	-1.3045540957015431		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-NYQHAVZB74-F	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	MPO	SNV	p.R421W	6	HTLLLWEHNR	HTLLLREHNR	10	17	58275646	G	A	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	3.368	3	2.325	0.2546191	1.458	0.331341	-0.083963387	no	0	-4.490050853695689		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-JYCMSZZQE9-K	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	ARHGAP28	SNV	p.K412E	3	MLEYQKILWK	MLKYQKILWK	10	18	6890062	A	G	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	2.304	5.5	6.766	0.2211914	0.206	0.218072	-0.034133006	no	0	0.3371934800710375		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-G7TBC3QRHS-9	OAF52DHL	Kidney	Clear Cell Renal Cell Carcinoma	C20orf27	SNV	p.C156Y	1	YVRVTVQARVM	CVRVTVQARVM	11					HLA-B07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	5.083	0.5	3.543	0.020636627	0.374		-1.297797432	no	0	3.868597856901992		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-D85SAX278W-D	IAXGKPRY	Kidney	Clear Cell Renal Cell Carcinoma	OR4C6	SNV	p.S50C	3	ITCQSLRSPMY	ITSQSLRSPMY	11	11	55665314	A	T	HLA-A01:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.918	0.03	1.948	0.009559649	2.944	0.900234	0.884661186	no	0	-9.965784284662089		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-V7HHKJBHX0-B	IAXGKPRY	Kidney	Clear Cell Renal Cell Carcinoma	FZD6	SNV	p.P30A	4	ITVARCMKMAY	ITVPRCMKMAY	11	8	103300195	C	G	HLA-A01:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	2.998	0.15	1.958	0.0441262	3.082	0.757996	0.758620094	no	0	3.163703529564198		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-KPAPP08JZN-4	IAXGKPRY	Kidney	Clear Cell Renal Cell Carcinoma	TEAD2	SNV	p.L407Q	7	YMMNSVQENF	YMMNSVLENF	10	12	3040237	T	A	HLA-B44:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	9.908	5	6.214	0.04993693	2.628	0.195404	-0.378942333	no	0	2.498187423666854		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-H269NY9Y4N-4	IAXGKPRY	Kidney	Clear Cell Renal Cell Carcinoma	OR5K3	SNV	p.I208M	3	IQMFTIVLVSY	IQIFTIVLVSY	11	3	98391289	C	G	HLA-B44:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	12.817	0.4	1.108	0.008547084	3.242	0.855517	-0.051102124	no	0	-9.965784284662089		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-PMTES560GN-4	IAXGKPRY	Kidney	Clear Cell Renal Cell Carcinoma	YOD1	SNV	p.S9L	9	METLHIIYLEA	METLHIIYSEA	11	1	207052210	G	A	HLA-B44:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	13.223	9	2.941	0.030333834	-0.564		-0.023912071	no	0	0.7847117769866219		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-JDV9ZVKS42-D	IAXGKPRY	Kidney	Clear Cell Renal Cell Carcinoma	ERCC8	SNV	p.G221V	6	VRRASVCLITL	VRRASGCLITL	11	5	60899683	C	A	HLA-C07:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	3.521	12	3.976	0.10584346	1.416	0.918339	0.165145293	no	0	-0.3725801240538413		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-G3BE79QGN2-D	BOGIVUKN	Kidney	Clear Cell Renal Cell Carcinoma	GLG1	SNV	p.L338I	6	RVYKCIFNH	RVYKCLFNH	9	16	74494798	G	T	HLA-A03:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.249	0.5	0.008	0.39178392	0.178	0.097848	-0.337619026	no	0	4.478185491730762		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-YYZ3HZCGF7-I	BOGIVUKN	Kidney	Clear Cell Renal Cell Carcinoma	GLG1	SNV	p.L338I	6	RVYKCIFNHK	RVYKCLFNHK	10	16	74494798	G	T	HLA-A03:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.056	0.01	0.004	0.68185747	1.178	0.961058	-0.356674944	no	0	4.478185491730762		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-M8B2NH5486-H	BOGIVUKN	Kidney	Clear Cell Renal Cell Carcinoma	SRD5A2	SNV	p.A217T	7	LPALAFTFFSL	LPALAFAFFSL	11	2	31529356	C	T	HLA-B07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.672	0.2	0.14	0.08084268	0.46	0.971422	-0.418279478	no	0	-5.8489265178067225		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-82P7M58FXX-E	BOGIVUKN	Kidney	Clear Cell Renal Cell Carcinoma	CD1C	SNV	p.V311M	1	MPLVILIVL	VPLVILIVL	9	1	158293253	G	A	HLA-B07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.586	0.9	0.017	0.7926122	0.438	0.917668	-0.00170503	no	0	-0.9160941974071436		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-6TCSWHS4A6-H	BOGIVUKN	Kidney	Clear Cell Renal Cell Carcinoma	CD1C	SNV	p.V311M	1	MPLVILIVLVL	VPLVILIVLVL	11	1	158293253	G	A	HLA-B07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	4.057	0.9	0.853	0.116057985	0.438	0.883395	-0.074319225	no	0	-0.9160941974071436		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-5ECRJQSBEH-Z	HRJPSEJN	Kidney	Clear Cell Renal Cell Carcinoma	ABCC12	SNV	p.Q663K	1	KFLESCDEVI	QFLESCDEVI	10	16	48115417	G	T	HLA-A24:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	4.435	1.3	2.46	0.05148891	0.838	0.231093	-0.548310376	no	0	-9.965784284662089		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-0WQ2MP5DZM-3	HRJPSEJN	Kidney	Clear Cell Renal Cell Carcinoma	PCDH11X	SNV	p.V471I	7	VFTQSFITVSI	VFTQSFVTVSI	11	X	91877651	G	A	HLA-A24:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	3.251	1	2.133	0.03491083	0.622	0.920262	0.089727514	no	0	-8.702749878828293		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-55NKH7X9AM-3	HRJPSEJN	Kidney	Clear Cell Renal Cell Carcinoma	KCNA10	SNV	p.V324F	10	YFATLITELF	YFATLITELV	10	1	110517818	C	A	HLA-C04:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	2.709	2.5	0.213	0.5196818	2.53	0.965234	-1.027745596	no	0	-9.965784284662089		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-1X2QPD84BC-U	HRJPSEJN	Kidney	Clear Cell Renal Cell Carcinoma	GYS1	SNV	p.D219Y	8	YLCAGAVYF	YLCAGAVDF	9	19	48985873	C	A	HLA-C04:01	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	2.729	7.5	0.937	0.11045939	2.406	0.613652	-0.708059259	no	0	4.514850523982965		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-6YS6KZF0ZJ-0	CWS5ZPHH	Kidney	Clear Cell Renal Cell Carcinoma	SAMD9	SNV	p.V853L	7	IPDSIALIQQL	IPDSIAVIQQL	11	7	93103541	C	G	HLA-B07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.785	1.8	0.721	0.1560137	-0.004	0.939483	0.020592748	no	0	2.005937758649707		PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-XRN8FZGYB9-K	CWS5ZPHH	Kidney	Clear Cell Renal Cell Carcinoma	FAM46D	SNV	p.G140R	2	NRHDCWSLISL	NGHDCWSLISL	11	X	80442957	G	A	HLA-C07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	1.435	7.5	1.437	0.38482612	1.566		-2.943888672	no	0			PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-86Q5CKJV2V-C	CWS5ZPHH	Kidney	Clear Cell Renal Cell Carcinoma	TMEM14B	SNV	p.S48L	7	GRQSWSLYV	GRQSWSSYV	9	6	10756495	C	T	HLA-C07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	0.943	28	0.711	0.6849103	0.46		-0.809633276	no	0	2.6366708870508737	Other Tumor Driver	PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-35E95E8DZT-A	CWS5ZPHH	Kidney	Clear Cell Renal Cell Carcinoma	ATP5L	SNV	p.E37D	8	FWYYAKVDL	FWYYAKVEL	9	11	118406995	G	C	HLA-C07:02	CD8	"ELISPOT, ICS, multimer"	patient_Tc_line	"peptide_pulsed_APC, tumor_cells"	none	1.287	5	2.884	0.6691152	1.222		1.654737672	no	0			PMID:32226429	Tumor-Infiltrating T Cells From Clear Cell Renal Cell Carcinoma Patients Recognize Neoepitopes Derived From Point and Frameshift Mutations
NDDR-TAN0D6MD3E-W	N6KFWJQT	Skin	Skin Cutaneous Melanoma	ZNF878	SNV	p.T216A	10	ALSYLVSFQR	ALSYLVSFQT	10	19	12044754	G	C	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	peptide_pulsed_APC	none	0.864	1.8	0.924	0.08088384	1.742	0.268499	-3.411941921	no	0	-3.561495225707876		PMID:32582212	Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
NDDR-K21F4K6BFN-4	4AYY5TKK	Skin	Skin Cutaneous Melanoma	IFT80	SNV	p.H63Y	9	DDIYPIDFY	DDIYPIDFH	9	3	160381575	G	A	HLA-A25:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	peptide_pulsed_APC	none	2.71	15	2.041	0.014567288	2.476	0.031321	-1.979294962	no	0	0.6151337575144284		PMID:32582212	Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
NDDR-TB0YN7HNPM-3	EC43Q54U	Skin	Skin Cutaneous Melanoma	PTPRU	SNV	p.P783L	9	DHYAYSYYL	DHYAYSYYP	9	1	29289712	C	T	HLA-C06:02	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	peptide_pulsed_APC	none	1.063	32	0.426	0.033498265	0.96	0.047113	-3.101210374	no	0	0.9139071064582698		PMID:32582212	Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
NDDR-KZB4CT37FG-Y	BJGJ7IRT	Skin	Skin Cutaneous Melanoma	PRICKLE3	SNV	p.E566K	1	KRIPLPPHLC	ERIPLPPHLC	10	X	49175825	C	T	HLA-C06:02	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	peptide_pulsed_APC	none	1.568	34	2.369	0.047567155	0.624	0.048856	-0.456035352	no	0	1.906736681459138		PMID:32582212	Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
NDDR-E4C0EFBDYG-Y	B5DYJLWE	Skin	Skin Cutaneous Melanoma	IQCF2	SNV	p.A66V	9	LVRRTLLHV	LVRRTLLHA	9	3	51874079	G	A	HLA-C15:02	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	peptide_pulsed_APC	none	1.337	4	0.435	0.012773356	0.584	0.267439	-1.746888317	no	0	-9.965784284662089		PMID:32582212	Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
NDDR-DPWR40BZ71-C	5UPLPDEU	Skin	Skin Cutaneous Melanoma	IPO8	SNV	p.S357F	9	NISEDVIFF	NISEDVIFS	9	12	30669257	G	A	HLA-A25:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	peptide_pulsed_APC	none	0.294	4	0.44	0.001440531	2.882	0.030009	-4.614210829	no	0	3.321793844815637		PMID:32582212	Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
NDDR-7RGBS210TA-S	GNOPTMJG	Skin	Skin Cutaneous Melanoma	B4GALNT3	SNV	p.M544V	8	PVKNLPQV	PVKNLPQM	8	12	553553	A	G	HLA-B51:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	peptide_pulsed_APC	none	1.043	18	44.895	0.35037833	0.096	0.97563	-1.179023687	yes	0	1.239090613533076		PMID:32582212	Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
NDDR-WVB22RGYC4-F	N6KFWJQT	Skin	Skin Cutaneous Melanoma	TRIOBP	SNV	p.S826T	11	RTSSTQQDNPK	RTSSTQQDNPQ	11	22	37725032	T	A	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	peptide_pulsed_APC	none	0.297	0.12	1.911	0.017354071	0.704	0.106883	-3.408577489	no	0	3.3747612795662447		PMID:32582212	Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
NDDR-PZNWG95E5N-4	N6KFWJQT	Skin	Skin Cutaneous Melanoma	PRICKLE3	SNV	p.E566K	11	SSEDDGFFLGK	SSEDDGFFLGE	11	X	49175825	C	T	HLA-A11:01	CD8	"ELISPOT, ICS, multimer"	"PBMC_pre, PBMC_postVax"	peptide_pulsed_APC	none	0.715	1.7	0.622	0.17497762	0.328	0.092192	-3.631309602	no	0	1.906736681459138		PMID:32582212	Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF
